QuickLinksTable of Contents-- Click here to rapidly navigate through this document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 10-Q

(Mark One)  
ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended September 30, 2008March 31, 2009

Or

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                        to                         

Commission File No. 1-6639

MAGELLAN HEALTH SERVICES, INC.
(Exact name of registrant as specified in its charter)

Delaware 58-1076937
(State or other jurisdiction of
incorporation or organization)
 (IRS Employer
Identification No.)

55 Nod Road, Avon, Connecticut

 

06001
(Address of principal executive offices) (Zip code)

(860) 507-1900
(Registrant's telephone number, including area code)



        Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý    No o

        Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filerý Accelerated filero Non-accelerated filero
(Do not check if a smaller
reporting company)
 Smaller reporting companyo

        Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o    No o

        Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o    No ý

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

        Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ý    No o

        The number of shares of the registrant's Ordinary Common Stock outstanding as of September 30, 2008March 31, 2009 was 40,453,168.35,296,577.


Table of Contents

FORM 10-Q

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

INDEX

 
  
 Page No. 

PART I—Financial Information:

    

Item 1:

 

Financial Statements

  3 

 

Condensed Consolidated Balance Sheets—December 31, 20072008 and September 30, 2008March 31, 2009

  3 

 

Condensed Consolidated Statements of Income—For the Three Months Ended March 31, 2008 and Nine Months Ended September 30, 2007 and 20082009

  4 

 

Condensed Consolidated Statements of Cash Flows—For the NineThree Months Ended September 30, 2007March 31, 2008 and 20082009

  5 

 

Notes to Condensed Consolidated Financial Statements

  6 

Item 2:

 

Management's Discussion and Analysis of Financial Condition and Results of Operations

  2219 

Item 3:

 

Quantitative and Qualitative Disclosures About Market Risk

  3832 

Item 4:

 

Controls and Procedures

  3833 

PART II—Other Information:

    

Item 1:

 

Legal Proceedings

  4034 

Item 1A:

Risk Factors

40

Item 2:

 

Unregistered Sales of Equity Securities and Use of Proceeds

  4134 

Item 3:

 

Defaults Upon Senior Securities

  4135 

Item 4:

 

Submission of Matters to a Vote of Security Holders

  4135 

Item 5:

 

Other Information

  4235 

Item 6:

 

Exhibits

  4235 

Signatures

  4336 

Table of Contents


PART I—FINANCIAL INFORMATION

Item 1.    Financial Statements.


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)



 December 31,
2007
 September 30,
2008
 
 December 31,
2008
 March 31,
2009
 


  
 (unaudited)
 
  
 (unaudited)
 

ASSETS

ASSETS

 

ASSETS

 

Current Assets:

Current Assets:

 

Current Assets:

 

Cash and cash equivalents

Cash and cash equivalents

 $312,372 $262,505 

Cash and cash equivalents

 $211,825 $178,282 

Restricted cash

Restricted cash

 252,763 149,159 

Restricted cash

 192,395 128,039 

Accounts receivable, less allowance for doubtful accounts of $1,317 and $1,724 at December 31, 2007 and September 30, 2008, respectively

 66,356 91,316 

Short-term investments (restricted investments of $12,962 and $139,494 at December 31, 2007 and September 30, 2008, respectively)

 54,145 306,439 

Accounts receivable, less allowance for doubtful accounts of $1,915 and $1,689 at December 31, 2008 and March 31, 2009, respectively

Accounts receivable, less allowance for doubtful accounts of $1,915 and $1,689 at December 31, 2008 and March 31, 2009, respectively

 82,076 84,312 

Short-term investments (restricted investments of $116,112 and $143,422 at December 31, 2008 and March 31, 2009, respectively)

Short-term investments (restricted investments of $116,112 and $143,422 at December 31, 2008 and March 31, 2009, respectively)

 225,372 243,126 

Deferred income taxes

Deferred income taxes

 75,273 75,273 

Deferred income taxes

 58,092 58,092 

Other current assets (restricted deposits of $19,388 and $20,905 at December 31, 2007 and September 30, 2008, respectively)

 42,183 48,690 

Other current assets (restricted deposits of $17,769 and $16,896 at December 31, 2008 and March 31, 2009, respectively)

Other current assets (restricted deposits of $17,769 and $16,896 at December 31, 2008 and March 31, 2009, respectively)

 52,660 43,994 
           

Total Current Assets

 803,092 933,382 

Total Current Assets

Total Current Assets

 822,420 735,845 

Property and equipment, net

Property and equipment, net

 105,735 90,168 

Property and equipment, net

 88,436 84,615 

Long-term investments—restricted

Long-term investments—restricted

 2,430 1,946 

Long-term investments—restricted

 8,527 18,747 

Deferred income taxes

Deferred income taxes

 90,618 61,572 

Deferred income taxes

 76,769 71,488 

Other long-term assets

Other long-term assets

 6,197 4,512 

Other long-term assets

 3,472 3,604 

Goodwill

Goodwill

 367,872 367,423 

Goodwill

 367,325 367,325 

Other intangible assets, net

Other intangible assets, net

 59,179 52,755 

Other intangible assets, net

 50,615 48,474 
           
 

Total Assets

 $1,435,123 $1,511,758 

Total Assets

Total Assets

 $1,417,564 $1,330,098 
           

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES AND STOCKHOLDERS' EQUITY

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

Current Liabilities:

Current Liabilities:

 

Current Liabilities:

 

Accounts payable

Accounts payable

 $25,952 $32,258 

Accounts payable

 $21,527 $24,651 

Accrued liabilities

Accrued liabilities

 79,699 107,216 

Accrued liabilities

 96,533 71,649 

Medical claims payable

Medical claims payable

 162,666 162,659 

Medical claims payable

 155,860 142,875 

Other medical liabilities

Other medical liabilities

 93,573 86,009 

Other medical liabilities

 99,953 88,504 

Current maturities of long-term debt and capital lease obligations

Current maturities of long-term debt and capital lease obligations

 13,969 1,302 

Current maturities of long-term debt and capital lease obligations

 8 7 
           

Total Current Liabilities

 375,859 389,444 

Total Current Liabilities

Total Current Liabilities

 373,881 327,686 

Long-term debt and capital lease obligations

Long-term debt and capital lease obligations

  27 

Long-term debt and capital lease obligations

 20 14 

Deferred credits and other long-term liabilities

Deferred credits and other long-term liabilities

 150,433 128,533 

Deferred credits and other long-term liabilities

 135,590 134,875 

Minority interest

 599 599 
           

Total Liabilities

 526,891 518,603 

Total Liabilities

Total Liabilities

 509,491 462,575 
           

Preferred stock, par value $.01 per share

Preferred stock, par value $.01 per share

 

Preferred stock, par value $.01 per share

 

Authorized—10,000 shares—Issued and outstanding—none

Authorized—10,000 shares—Issued and outstanding—none

   

Authorized—10,000 shares—Issued and outstanding—none

   

Ordinary common stock, par value $.01 per share

Ordinary common stock, par value $.01 per share

 

Ordinary common stock, par value $.01 per share

 

Authorized—100,000 shares at December 31, 2007 and September 30, 2008—Issued and outstanding—40,157 shares at December 31, 2007 and 40,848 shares issued and 40,453 shares outstanding at September 30, 2008

 402 408 

Authorized—100,000 shares at December 31, 2008 and March 31, 2009—Issued and outstanding—40,873 shares and 40,963 shares at December 31, 2008 and March 31, 2009, respectively

 409 410 

Multi-Vote common stock, par value $.01 per share

Multi-Vote common stock, par value $.01 per share

 

Multi-Vote common stock, par value $.01 per share

 

Authorized—40,000 shares—Issued and outstanding—none

   

Authorized—40,000 shares—Issued and outstanding—none

   

Other Stockholders' Equity:

Other Stockholders' Equity:

 

Other Stockholders' Equity:

 

Additional paid-in capital

Additional paid-in capital

 589,011 597,017 

Retained earnings

Retained earnings

 449,252 462,812 

Warrants outstanding

Warrants outstanding

 5,382 5,382 

Accumulated other comprehensive income (loss)

Accumulated other comprehensive income (loss)

 172 (114)

Ordinary common stock in treasury, at cost, 3,867 shares and 5,666 shares at December 31, 2008 and March 31, 2009, respectively

Ordinary common stock in treasury, at cost, 3,867 shares and 5,666 shares at December 31, 2008 and March 31, 2009, respectively

 (136,153) (197,984)

Additional paid-in capital

 539,374 580,214       

Total Stockholders' Equity

Total Stockholders' Equity

 908,073 867,523 

Retained earnings

 363,047 425,668       

Total Liabilities and Stockholders' Equity

Total Liabilities and Stockholders' Equity

 $1,417,564 $1,330,098 

Warrants outstanding

 5,384 5,382       

Accumulated other comprehensive income (loss)

 25 (1,841)

Ordinary common stock in treasury, at cost, 0 shares and 395 shares at December 31, 2007 and September 30, 2008, respectively

  (16,676)
     

Total Stockholders' Equity

 908,232 993,155 
     
 

Total Liabilities and Stockholders' Equity

 $1,435,123 $1,511,758 
     

See accompanying notes to condensed consolidated financial statements.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED MARCH 31,

(Unaudited)

(In thousands, except per share amounts)



 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 


 2007 2008 2007 2008 
 2008 2009 

Net revenue

Net revenue

 $558,076 $656,462 $1,497,948 $1,963,610 

Net revenue

 $650,290 $619,515 
               

Cost and expenses:

Cost and expenses:

 

Cost and expenses:

 

Cost of care

 369,008 456,584 957,045 1,368,748 

Cost of care

 454,074 431,718 

Cost of goods sold

 37,341 44,281 108,052 134,518 

Cost of goods sold

 46,824 52,072 

Direct service costs and other operating expenses(1)

 102,468 105,879 298,482 322,110 

Direct service costs and other operating expenses(1)

 109,748 103,064 

Depreciation and amortization

 14,393 16,086 41,550 44,983 

Depreciation and amortization

 14,374 11,043 

Interest expense

 1,571 592 5,027 2,824 

Interest expense

 1,215 427 

Interest income

 (6,434) (4,127) (17,140) (13,336)

Interest income

 (5,493) (2,311)
               

 518,347 619,295 1,393,016 1,859,847 

 620,742 596,013 
               

Income from continuing operations before income taxes and minority interest

 39,729 37,167 104,932 103,763 

Income from continuing operations before income taxes

Income from continuing operations before income taxes

 29,548 23,502 

Provision for income taxes

Provision for income taxes

 14,712 13,738 41,930 41,142 

Provision for income taxes

 12,304 9,942 
               

Income from continuing operations before

 

minority interest

 25,017 23,429 63,002 62,621 

Minority interest, net

 (47) (60) 145  
         

Net income

Net income

 25,064 23,489 62,857 62,621 

Net income

 17,244 13,560 

Other comprehensive income (loss)

 48 (1,590) 40 (1,866)

Other comprehensive loss

Other comprehensive loss

 (14) (286)
               

Comprehensive income

Comprehensive income

 $25,112 $21,899 $62,897 $60,755 

Comprehensive income

 $17,230 $13,274 
               

Weighted average number of common shares outstanding—basic (See Note B)

Weighted average number of common shares outstanding—basic (See Note B)

 39,193 40,272 38,759 39,991 

Weighted average number of common shares outstanding—basic (See Note B)

 39,736 36,208 
               

Weighted average number of common shares outstanding—diluted (See Note B)

Weighted average number of common shares outstanding—diluted (See Note B)

 39,849 40,722 39,654 40,457 

Weighted average number of common shares outstanding—diluted (See Note B)

 40,340 36,386 
               

Net income per common share—basic:

Net income per common share—basic:

 $0.64 $0.58 $1.62 $1.57 

Net income per common share—basic:

 $0.43 $0.37 
               

Net income per common share—diluted:

Net income per common share—diluted:

 $0.63 $0.58 $1.59 $1.55 

Net income per common share—diluted:

 $0.43 $0.37 
               

(1)
Includes stock compensation expense of $8,172$12,018 and $7,832$6,432 for the three months ended September 30, 2007March 31, 2008 and 2008, respectively, and $22,662 and $26,349 for the nine months ended September 30, 2007 and 2008,2009, respectively.

See accompanying notes to condensed consolidated financial statements.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINETHREE MONTHS ENDED SEPTEMBER 30,MARCH 31,

(Unaudited)

(In thousands)


 2007 2008  2008 2009 

Cash flows from operating activities:

  

Net income

 $62,857 $62,621  $17,244 $13,560 

Adjustments to reconcile net income to net cash provided by operating activities:

  

Depreciation and amortization

 41,550 44,983  14,374 11,043 

Non-cash interest expense

 1,042 1,730  573 232 

Non-cash stock compensation expense

 22,662 26,349  12,018 6,432 

Non-cash income tax expense

 38,987 32,339  10,586 4,639 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

  

Restricted cash

 (48,339) 103,604  (10,435) 64,356 

Accounts receivable, net

 (3,520) (24,960) (15,063) (2,236)

Other assets

 (9,747) (6,012) 4,997 8,297 

Accounts payable and accrued liabilities

 (5,411) 3,752  (15,778) (23,813)

Medical claims payable and other medical liabilities

 51,925 (7,571) (5,532) (24,434)

Other

 535 (68) (537) 568 
          

Net cash provided by operating activities

 152,541 236,767  12,447 58,644 
          

Cash flows from investing activities:

  

Capital expenditures

 (31,806) (23,955) (7,979) (5,310)

Acquisitions and investments in businesses, net of cash acquired

 (5,277) (425) (425)  

Purchase of investments

 (100,883) (345,702) (35,013) (77,730)

Maturity of investments

 94,017 92,992  53,130 48,757 
          

Net cash used in investing activities

 (43,949) (277,090)

Net cash provided by (used in) investing activities

 9,713 (34,283)
          

Cash flows from financing activities:

  

Payments on long-term debt and capital lease obligations

 (20,346) (12,686) (4,307) (2)

Payments to acquire treasury stock

  (13,523)  (59,476)

Proceeds from exercise of stock options and warrants

 26,717 12,587  4,010 912 

Other

 (172) 4,078  (1,456) 662 
          

Net cash provided by (used in) financing activities

 6,199 (9,544)

Net cash used in financing activities

 (1,753) (57,904)
          

Net increase (decrease) in cash and cash equivalents

 114,791 (49,867) 20,407 (33,543)

Cash and cash equivalents at beginning of period

 163,737 312,372  312,372 211,825 
          

Cash and cash equivalents at end of period

 $278,528 $262,505  $332,779 $178,282 
          

See accompanying notes to condensed consolidated financial statements.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General

Basis of Presentation

        The accompanying unaudited condensed consolidated financial statements of Magellan Health Services, Inc., a Delaware corporation ("Magellan"), include the accounts of Magellan, its majority owned subsidiaries, and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company"). The financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the Securities and Exchange Commission's (the "SEC") instructions to Form 10-Q. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The results of operations for the ninethree months ended September 30, 2008March 31, 2009 are not necessarily indicative of the results to be expected for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

        These unaudited condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 20072008 and the notes thereto, which are included in the Company's Annual Report on Form 10-K filed with the SEC on February 29, 2008.27, 2009.

Business Overview

        The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. During 2006, the Company expanded into radiology benefits management and specialty pharmaceutical management as a result of certain acquisitions. The Company provides services to health plans, insurance companies, corporations, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

        Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide, or own any provider of, treatment services except as relates to the Company's contract to provide managed behavioral healthcare services to Medicaid recipients and other beneficiaries of the Maricopa County Regional Behavioral Health Authority (the "Maricopa Contract"). Under the Maricopa Contract, effective August 31, 2007 the


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


Company was required to assume the operations of twenty-four behavioral health direct care facilities for a transitional period and to divest itself of these facilities over a two year period. During AugustMarch 2009, the Company began the operation of two additional behavioral health direct care facilities. At various dates in 2008 and October 2008,2009, the Company entered into agreements with twothree separate Provider Network Organizations ("PNOs") which



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)


will result into transition 20 of the transition of thirteen of such26 behavioral health direct care facilities to the PNOs over various datesdates. Fourteen of such direct care facilities have been transitioned through FebruaryApril 2009 and the Company expects to divest itself of the remainder of these facilities before August 31, 2009.

        The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

        The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

        Commercial.    The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations and governmental agencies, and labor unions. Commercial's managed behavioral healthcare contracts encompass either risk-based, or ASO arrangements or both. This segment contains the operating segments previously defined as the Managed Behavioral Healthcare Health Plan Segment ("Health Plan") and the Managed Behavioral Healthcare Employer segment ("Employer"). Prior period balances have been reclassified to reflect this change. The Company now considers Commercial as one segment and it is managed as such.EAP arrangements.

        Public Sector.    The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects managed behavioral healthcare services provided to Medicaid recipients under contracts with state and local governmental agencies. Public Sector contracts encompass either risk-based or ASO arrangements.

Radiology Benefits Management.Management

        The Company's Radiology Benefits Management segment generally reflects the management of the delivery of diagnostic imaging services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided throughunder contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members of the health plan.members. The Company also has abid on contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company has won one state Medicaid contract, with a state agency.which was implemented in July 2008. The Company offers its radiology benefits management services through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services, and through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services. The Company's first two risk-based radiology benefits management contracts became effective June 1, 2007 and July 1, 2007.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


Specialty Pharmaceutical Management.Management

        The Company's Specialty Pharmaceutical Management segment generally reflects the management of specialty drugs used in the treatment of cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis and other diseases.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)


Specialty pharmaceutical drugs represent high-cost injectible, infused, oral, or inhaled drugs which traditional retail pharmacies typicallyoften do not supply due to their high cost, sensitive handling, and storage needs. The Company's specialty pharmaceutical management services are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicare and Medicaid members. The Company's specialty pharmaceutical services include (i) contracting and formulary optimization on behalf of health plans and pharmaceutical manufacturers; (ii) distributing specialty pharmaceutical drugs on behalf of health plans, (ii) administering on behalf of health plans rebate agreements between health plans and pharmaceutical manufacturers, andplans; (iii) providing strategic consulting services to health plans and pharmaceutical manufacturers.manufacturers; and (iv) providing oncology benefits management services to health plans.

Corporate and Other.Other

        This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

Summary of Significant Accounting Policies

Recent Accounting Pronouncements

        In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157 ("SFAS 157"), which provides guidance for using fair value to measure assets and liabilities. It also responds to investors' requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position No. 157-2, Effective Date of FASB Statement No. 157 ("FSP 157-2"), which delays the effective date of SFAS 157 by one year for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). On January 1, 2008, the Company adopted SFAS 157 for financial assets and liabilities. The adoption did not have a material impact on the consolidated financial statements. TheOn January 1, 2009, the Company has not yet determined the impact on its consolidated financial statements, if any, from the adoption ofadopted SFAS 157 as it pertains tofor non-financial assets and non-financial liabilities.

        In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115" ("SFAS 159"). SFAS 159 permits entities to elect to measure financial instruments and certain other items at fair value. The objective is to improve financial reporting by allowing entities to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. SFAS 159 was effective for the Company on January 1, 2008. The Companyadoption did not electhave a material impact on the fair value option for any of the Company's existingconsolidated financial instruments on January 1, 2008 and has not determined whether or not the Company will elect this option for any eligible financial instruments the Company acquires in the future.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)statements.

        In December 2007, the FASB issued SFAS No. 141(R) "Business Combinations" ("SFAS 141(R)") and SFAS No. 160, "Non-controlling Interests in Consolidated Financial Statements" ("SFAS 160"). SFAS 141(R) requires the acquiring entity in a business combination to record all assets acquired and liabilities assumed at their respective acquisition-date fair values and changes other practices under


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)


SFAS 141, some of which could have a material impact on how the Company accounts for future business combinations. SFAS 141(R) also requires additional disclosure of information surrounding a business combination, such that users of the entity's financial statements can fully understand the nature and financial impact of the business combination. SFAS 160 requires entities to report non-controlling (minority) interests in subsidiaries as equity in the consolidated financial statements. The Company is required to adoptadopted SFAS 141(R) and SFAS 160 simultaneously in the Company's year beginning January 1, 2009. The Company is currently evaluatingPrior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the effects, if any, thatBankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to the Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax expense. As a result of the implementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits are reflected as reductions to income tax expense, even if related to years prior to the Company's reorganization. The adoption of SFAS 160 maydid not have a material impact on the Company's consolidated financial position and results of operations.statements.

Use of Estimates

        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, stock compensation assumptions, tax contingencies and legal liabilities. Actual results could differ from those estimates.

Managed Care Revenue

        Managed care revenue, inclusive of revenue from the Company's risk, EAP and ASO contracts, is recognized over the applicable coverage period on a per member basis for covered members. The Company is paid a per member fee for all enrolled members, and this fee is recorded as revenue in the month in which members are entitled to service. The Company adjusts its revenue for retroactive membership terminations, additions and other changes, when such adjustments are identified, with the exception of retroactivity that can be reasonably estimated. Any fees paid prior to the month of service are recorded as deferred revenue. Managed care revenues approximated $513.0$593.3 million and $1,367.2$554.2 million for the three and nine months ended September 30, 2007, respectively,March 31, 2008 and $599.7 million and $1,795.5 million for the three and nine months ended September 30, 2008,2009, respectively.

Cost-Plus Contracts

        The Company has certain cost-plus contracts fromwith customers under which the Company recognizes revenue as costs are incurred and as services are performed. Revenues from cost-plus contracts approximated $7.7$7.2 million and $22.7$7.5 million for the three and nine months ended September 30, 2007, respectively,March 31, 2008 and $8.2 million and $23.7 million for the three and nine months ended September 30, 2008,2009, respectively.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General (Continued)

Block Grant Revenues

        The Maricopa Contract is partially funded by federal, state and county block grant money, which represents annual appropriations. The Company recognizes revenue from block grant activity ratably over the period to which the block grant funding applies. Block grant revenues were approximately $10.2 million for both the three and nine months ended September 30, 2007, and $29.5$30.6 million and $90.7$25.5 million for the three and nine months ended September 30,March 31, 2008 and 2009, respectively.

Distribution Revenue

        The Company recognizes distribution revenue, which includes the co-payments received from members of the health plans the Company serves, when the specialty pharmaceutical drugs are shipped. At the time of shipment, the earnings process is complete:complete; the obligation of the Company's customer to pay for the specialty pharmaceutical drugs is fixed, and, due to the nature of the product, the member may notneither return the specialty pharmaceutical drugs nor receive a refund. Revenues from the distribution of specialty pharmaceutical drugs on behalf of health plans were $40.0$50.0 million and $116.6$56.6 million for the three and nine months ended September 30, 2007, respectively,March 31, 2008 and $47.7 million and $144.6 million for the three and nine months ended September 30, 2008,2009, respectively.

Performance-based Revenue

        The Company has the ability to earn performance-based revenue under certain risk and non-risk contracts. Performance-based revenue generally is based on either the ability of the Company to manage care for its clients below specified targets, or on other operating metrics. For each such contract, the Company estimates and records performance-based revenue after considering the relevant contractual terms and the data available for the performance-based revenue calculation. Pro-rata performance-based revenue is recognized on an interim basis pursuant to the rights and obligations of each party upon termination of the contracts. Performance-based revenues were $2.6$3.9 million and $5.8$1.3 million for the three and nine months ended September 30, 2007, respectively,March 31, 2008 and $1.9 million and $8.2 million for the three and nine months ended September 30, 2008,2009, respectively.

Significant Customers

        The Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008 and 2009. In addition to the Maricopa Contract, the Company's contractscontract with the State of Tennessee's TennCare program ("TennCare") generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the ninethree months ended September 30, 2007. In addition to TennCare, the Company's Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the nine months ended September 30,March 31, 2008. The Company also has a significant concentration of business from contracts with subsidiaries of WellPoint, Inc. ("WellPoint") and from contracts with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)

        The Maricopa Contract, which began September 1, 2007 and which extends through June 30, 2010, generated net revenues of $48.1$149.5 million and $455.5$168.5 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively.


        The Company provides managed behavioral healthcare services for TennCare through contracts that extend through various dates.Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE A—General (Continued)

        The TennCare program is divided into three regions, and through March 31, 2007 the Company's TennCare contracts encompassed all of the TennCare membership for all three regions. As of April 1, 2007 substantially all of the membership in the Middle Grand Region was re-assigned to managed care companies in accordance with contract awards by TennCare pursuant to its request for proposals for the management of the integrated delivery of behavioral and physical medical care to the region. Substantially all of the membership in the West Grand and East Grand Regions willwas similarly be re-assigned to managed care companies in accordance with contract awards by TennCare effective November 1, 2008 and January 1, 2009, respectively. The Company continues to manage behavioral healthcare services for children enrolled in TennCare Select High, statewide, as well as for certain out-of-state TennCare members pursuant to contracts that extend through June 30, 2009. The Company recorded net revenues of $245.2$70.8 million and $217.1$12.8 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively, from its TennCare contracts. The portion of the total net revenues associated with the programs for children and out-of-state members referred to above was $33.8 million and $34.2 million for the nine months ended September 30, 2007 and 2008, respectively.

        Total net revenues from the Company's contracts with WellPoint were $155.7$51.6 million and $145.7$44.0 million during the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively, including radiology benefits management revenue of $44.7$42.0 million and $124.7$40.6 million, respectively. One of the Company's managed behavioral healthcare contracts with WellPoint was terminated by WellPoint effective March 31, 2007, and generated net revenues of $26.0 million during 2007. A second managed behavioral healthcare contract with WellPoint expired December 31, 2007 and generated net revenues of $63.9 million during the nine months ended September 30, 2007.

        In July 2007, WellPoint acquired a radiology benefits management company, and has expressed its intent to in-source all of its radiology benefits management contracts when such contracts expire. The Company hashad several radiology benefits management contracts with WellPoint including one that converted from an ASO arrangement to a risk arrangement effective July 1, 2007. Such risk contract originally had a three-year term through June 30, 2010, and cannot be terminated early, except for cause, as defined in the agreement. The term of this risk contract has been extended through December 31, 2010. The Company's other radiology benefits management ASO contracts with WellPoint generated $10.8$4.6 million of net revenues for the ninethree months ended September 30, 2008. Substantially all of this revenue relates toMarch 31, 2008, and these ASO contracts that have terms throughterminated at various dates in 2008.

        Net revenues from the Pennsylvania Counties in the aggregate totaled $198.5$71.3 million and $216.7$74.8 million for the ninethree months ended SeptemberMarch 31, 2008 and 2009, respectively.

        Two customers generated greater than ten percent of Commercial net revenues for the three months ended March 31, 2008 and 2009. The first customer has a contract that extends through December 31, 2012 and generated net revenues of $49.6 million and $57.3 million for the three months ended March 31, 2008 and 2009, respectively. The second customer has a contract that extends through June 30, 20072009 and generated net revenues of $22.1 million and $21.9 million for the three months ended March 31, 2008 and 2009, respectively. On April 30, 2009, the Company and this customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the third anniversary of the contract.

        In addition to the Maricopa Contract and TennCare, one other customer generated net revenues greater than ten percent of the net revenues for the Public Sector segment for the three months ended March 31, 2008 and 2009. This customer has a contract that extends through December 31, 2009 and generated net revenues of $37.2 million and $36.0 million, respectively. Pursuant to an RFP process,


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General (Continued)

        WellPoint generated greater than ten percentthe customer notified the Company of net revenuesits intent to award the contract to provide servicing beyond December 31, 2009. The award is subject to the negotiation and execution of a contract between the Company and the customer. The proposed new contract will have a term of 2.5 years beginning on January 1, 2010 with options for the Commercial segment forcustomer to extend the nine months ended September 30, 2007. Two other customers generated greater than ten percent of Commercial net revenues for the nine months ended September 30, 2007 and 2008. The first customer has a contract that extends through December 31, 2010 and generated net revenues of $129.3 million and $159.4 million for the nine months ended September 30, 2007 and 2008, respectively. The second customer has a contract that extends through June 30, 2009 and generated net revenues of $66.8 million and $67.7 million for the nine months ended September 30, 2007 and 2008, respectively.

        Maricopa and TennCare were the only customers with revenues greater than ten percentterm of the net revenuescontract for the Public Sector segment for the nine months ended September 30, 2008. For the nine months ended September 30, 2007,three one customer other than TennCare generated greater than ten percent of the net revenues for the Public Sector segment for such period. This customer has a contract that extends through June 30, 2009 and generated net revenues of $92.3 million and $106.0 million for the nine months ended September 30, 2007 and 2008, respectively.year terms.

        In addition to WellPoint, one other customer generated greater than ten percent of the net revenues for the Radiology Benefits Management segment for the ninethree months ended September 30, 2007March 31, 2008 and 2008.2009. This customer has a contract that extends through May 31, 2011 and generated net revenues of $34.5$24.9 million and $73.4$22.6 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively.

        Included in the Company's Specialty Pharmaceutical Management segment are fourfive customers that each exceeded ten percent of the net revenues for this segment for the ninethree months ended September 30, 2007. The fourMarch 31, 2008. Four of such customers generated $44.4$17.1 million, $25.5$13.6 million, $23.7$7.5 million, and $18.2$7.1 million of net revenues during the ninethree months ended September 30, 2007.March 31, 2008. The other contract generated net revenues of $7.2 million for the three months ended March 31, 2008, and this contract terminated as of December 31, 2008. For the ninethree months ended September 30, 2008, fiveMarch 31, 2009, four customers each exceeded ten percent of the net revenues for this segment. Four of such customers generated $52.9$20.2 million, $36.3$13.9 million, $21.1$9.3 million, and $20.2$7.3 million of net revenues during the ninethree months ended September 30, 2008.March 31, 2009. The otherpreviously mentioned contract that terminated as of December 31, 2008 generated net revenues for run-off activity of $21.1$6.6 million for the ninethree months ended September 30, 2008, and such customer has indicated that they do not intend to continue the contract inMarch 31, 2009.

Fair Value Measurements

        The Company adopted SFAS 157 on January 1, 2008. SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. Under generally accepted accounting practices, certain assets and liabilities must be measured at fair value, and SFAS 157 details the disclosures that are required for items measured at fair value.

        The Company has various financial instruments that must be measured under the new fair value standard including investments, which consist primarily of U.S. Government securities, obligations of



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)


government-sponsored enterprises, corporate debt securities and certificates of deposit. The Company currently does not have non-financial assets and non-financial liabilities that are required to be measured at fair value on a recurring basis. Pursuant to SFAS 157, financial assets and liabilities are to be measured using inputs from the three levels of the fair value hierarchy, which are as follows:

        In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets and liabilities that are required to be measured at fair value as of September 30, 2008March 31, 2009 (in thousands):


 Fair Value Measurements at
September 30, 2008
  Fair Value Measurements at March 31, 2009 

 Level 1 Level 2 Level 3 Total  Level 1 Level 2 Level 3 Total 

Cash and Cash Equivalents(1)

 $ $140,643 $ $140,643  $ $116,409 $ $116,409 

Restricted Cash(2)

  93,637  93,637   100,948  100,948 

Investments:

  

U.S. Government and agency securities

 687   687  685   685 

Obligations of government-sponsored enterprises(3)

  58,930  58,930   50,570  50,570 

Corporate debt securities

  211,999  211,999   184,349  184,349 

Taxable municipal bonds

  9,999  9,999 

Certificates of deposit

  26,770  26,770   26,269  26,269 
                  

 $687 $541,978 $ $542,665  $685 $478,545 $ $479,230 
                  

        The Company periodically evaluates whether any declines in the fair value of investments are other-than-temporary. This evaluation consists of a review of several factors, including but not limited



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)


to: the length of time and extent that a security has been in an unrealized loss position; the existence of an event that would impair the issuer's future earnings potential; the near-term prospects for recovery of the market value of a security; and the intent and ability of the Company to hold the security until the market value recovers. Declines in value below cost for investments where it is considered probable that all contractual terms of the investment will be satisfied, is due primarily to the recent volatility of securities markets, and where the Company intends and has the ability to hold the investment for a period of time sufficient to allow a market recovery, are not assumed to be other-than-temporary.

        These assets are carried at fair value, and the unrealized gains or losses are included in accumulated other comprehensive income as a separate component of shareholders' equity, unless the decline in value is deemed to be other-than-temporary. If a decline in value is deemed to be other-than-temporary, the cost basis of the impaired security is written down to fair value and a charge is taken through operations. The Company has concluded that the unrealized losses are temporary and the Company has the intent and ability to hold the securities until they recover or mature. Therefore, the Company has not recorded any other than temporary impairments.

Income Taxes

        The Company's effective income tax rate was 40.041.6 percent and 39.642.3 percent for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively. This rate differsThese rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes.

        The Company files a consolidated federal income tax return for the Company and its eighty-percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various state and local jurisdictions. The Company is no longer subject to additional federal income taxes for any tax year ended prior to 2005, although the Company's federal net operating loss carryovers ("NOLs") from such prior years remain subject to examination by the Internal Revenue Service ("IRS"). With few exceptions, the Company is also no longer subject to additional state or local income taxes for years prior to 2004 or, in a few jurisdictions, for the 2004 tax year as well.

        The statutes of limitation regarding substantially all of the remaining unrecognized state and local tax benefits for 2004 will expire during the fourth quarter of 2008. As a result, the Company anticipates that up to $4.0 million of gross unrecognized tax benefits (excluding interest costs) recorded as of September 30, 2008 could be reversed during the fourth quarter, substantially all of which would be recorded (net of the related indirect tax benefits) as a reduction to income tax expense.

Stock Compensation

        The Company measures stock compensation under SFAS No. 123 (revised 2004) "Share-Based Payment" ("SFAS 123R"). At December 31, 20072008 and September 30, 2008,March 31, 2009, the Company had equity-based employee incentive plans, which are described more fully in Note 7 in the Company's Annual Report on Form 10-K for the year ended December 31, 2007.2008. Under SFAS 123R, the Company recorded stock compensation expense of $8.2$12.0 million and $22.7$6.4 million for the three and nine months ended March 31, 2008


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General (Continued)


ended September 30, 2007, respectively, and $7.8 million and $26.3 million for the three and nine months ended September 30, 2008,2009, respectively. Stock compensation expense recognized in the condensed consolidated statements of income for the three and nine months ended September 30, 2007March 31, 2008 and 20082009 has been reduced for estimated forfeitures, estimated at two percent and fourfive percent, respectively.

        The weighted average grant date fair value of all stock options granted during the ninethree months ended September 30, 2008March 31, 2009 was $9.14$8.69 as estimated using the Black-Scholes-Merton option pricing model, which also assumed an expected volatility of 28.430.2 percent based on the historical volatility of the Company's stock price.

        SFAS 123R also requires the benefits of tax deductions in excess of recognized stock compensation expense to be reported as a financing cash flow, rather than as an operating cash flow. In the ninethree months ended September 30, 2007, the tax deductions related to stock compensation expense were not recognized because of the availability of NOLs,March 31, 2008 and thus there were no such financing cash flows reported. In the nine months ended September 30, 2008,2009, approximately $5.4$0.1 million and $1.1 million of benefits of such tax deductions related to stock compensation expense were realized and as such were reported as financing cash flows. Most of this amount was reflected as an increase to additional paid in capital, with the remainder recorded as an increase to tax contingencies.flows, respectively.

        Summarized information related to the Company's stock options for the ninethree months ended September 30, 2008March 31, 2009 is as follows:


 Options Weighted
Average
Exercise
Price
  Options Weighted Average
Exercise Price
 

Outstanding, beginning of period

 4,059,096 $36.68  4,668,490 $39.82 

Granted

 1,478,079 41.48  1,095,769 33.08 

Cancelled

 (297,766) 39.94  (167,007) 41.53 

Exercised

 (571,109) 22.03  (29,435) 30.99 
          

Outstanding, end of period

 4,668,300 39.79  5,567,817 38.49 
          

Vested and expected to vest at end of period

 4,496,067 39.75  5,386,817 38.53 
          

Exercisable, end of period

 1,980,308 $38.65  2,916,350 $39.09 
          

        Substantially allAll of the Company's options granted during the ninethree months ended September 30, 2008March 31, 2009 vest ratably on each anniversary date over the three years subsequent to grant, and all have a ten year life.

        Summarized information related to the Company's nonvested restricted stock awards for the three months ended March 31, 2009 is as follows:

 
 Shares Weighted
Average
Grant Date
Fair Value
 

Outstanding, beginning of period

  321,935 $42.92 

Awarded

  869  33.51 

Vested

  (25,717) 35.83 

Forfeited

  (481) 34.57 
      

Outstanding, ending of period

  296,606 $43.52 
      

Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General (Continued)

        Summarized information related to the Company's nonvested restricted stock awards and nonvested restricted stock units for the ninethree months ended September 30, 2008March 31, 2009 is as follows:


 Restricted Stock Awards Restricted Stock Units 

 Shares Weighted
Average
Grant Date
Fair Value
 Shares Weighted
Average
Grant Date
Fair Value
  Shares Weighted
Average
Grant Date
Fair Value
 

Outstanding, beginning of period

 601,384 $43.25 219,736 $40.57  176,112 $38.72 

Awarded

 41,190 37.10 112,874 35.81  121,065 32.91 

Vested

 (306,924) 43.23 (116,508) 40.50  (76,471) 32.60 

Forfeited

 (7,532) 30.74 (17,945) 39.32  (13,871) 39.78 
              

Outstanding, ending of period

 328,118 $42.78 198,157 $38.01  206,835 $37.51 
              

        Substantially all restrictedRestricted stock awards and all restricted stock units granted during the ninethree months ended September 30, 2008March 31, 2009 vest ratably on each anniversary date over the three years subsequent to grant.

        On February 27, 2008 the board of directors of the Company approved the 2008 Management Incentive Plan ("2008 MIP") and recommended it be submitted for approval by the Company's shareholders at the 2008 Annual Meeting of shareholders. The 2008 MIP is similar to the 2006 Management Incentive Plan ("2006 MIP") and the 2003 Management Incentive Plan ("2003 MIP"). The board of directors also authorized a total of up to 4.5 million shares of the Company's Common Stock (which amount will be increased by the amount of any future forfeitures under the 2006 MIP, the 2003 MIP and the Director Plan) to be available for issuance pursuant to the 2008 MIP. Each restricted stock unit or share of restricted stock issued under the 2008 MIP shall be counted as 1.9 option shares for the purpose of calculating shares awarded and shares remaining available for grant pursuant to the 2008 MIP. The 2008 MIP also provides that no further awards are to be made under the 2006 MIP, the 2003 MIP or the Director Plan, and any equity awards remaining available for issuance under such plans are no longer available for issuance except for any forfeitures or other recapture of equity awards previously made under such plans, which will be available for grant under the 2008 MIP. The 2008 MIP, unlike the 2006 MIP and the 2003 MIP, also permits the grant of performance based cash bonus awards to eligible employees and the grant of equity to directors of the Company.

        On February 27, 2008, the compensation committee of the board of the Company authorized the grant of stock options and restricted stock units to members of management pursuant to the 2008 MIP with such options and restricted stock units to be issued on March 5, 2008 pursuant to the Company's equity award policy. The options granted to management have a ten year term and an exercise price equal to the closing price of a share of Common Stock of the Company on NASDAQ on March 5, 2008, the date of grant of annual equity awards under the Company's equity award policy. The options and restricted stock units granted to management vest ratably on each anniversary date over the three years subsequent to grant, except that the vesting of certain of the restricted stock units are subject to satisfaction of certain performance targets.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE A—General (Continued)

        The compensation committee also granted to each independent member of the board on May 20, 2008 (the date of the 2008 Annual Meeting of Shareholders), that number of shares of restricted stock of the Company determined by dividing $125,000 by the closing price of a share of the Company's Common Stock on NASDAQ on May 20, 2008. In addition, the compensation committee granted to the chairman of the board on May 20, 2008, that number of shares of restricted stock of the Company determined by dividing $500,000 by the closing price of a share of the Company's Common Stock on NASDAQ on May 20, 2008. Such shares of restricted stock granted to directors will vest on May 20, 2009.

        The options and restricted stock units awarded to members of management and the directors as described above were subject to and conditioned upon shareholder approval of the 2008 MIP which occurred at the 2008 Annual Meeting of Shareholders of the Company. As such, these awards were not effectively granted nor was any stock compensation expense recorded until May 20, 2008.

Long Term Debt and Capital Lease Obligations

        On April 30, 2008, the Company entered into a credit facility with Deutsche Bank AG and Citigroup Global Markets Inc. that providesprovided for a $100.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "New"2008 Credit Facility"). On April 30, 2008, the Company's credit agreement with Deutsche Bank AG dated January 5, 2004, as amended (the "Credit Agreement") was terminated. Borrowings under the New2008 Credit Facility, will matureif any, matured on April 29, 2009. The New2008 Credit Facility iswas guaranteed by substantially all of the subsidiaries of the Company and iswas secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the New2008 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to the sum of (i) a borrowing margin of 1.00 percent plus (ii) (A) in the case of U.S. dollar denominated loans, the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (B) in the case of Eurodollar denominated loans, an interest rate which is a function of the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 1.125 percent. The commitment commission on the New2008 Credit Facility iswas 0.375 percent of the unused Revolving Loan Commitment.

        At September 30, 2008,March 31, 2009, the annual interest ratesrate on the Company's capital lease obligationsobligation due through 2011 werewas 6.87 percent to 7.17 percent. There were no Revolving Loan borrowings at September 30, 2008.March 31, 2009.

        On April 29, 2009, the Company entered into an amendment to the 2008 Credit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will mature on April 28, 2010. The 2009 Credit Facility is guaranteed by


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008March 31, 2009

(Unaudited)

NOTE A—General (Continued)


substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the 2009 Credit Facility is 0.625 percent of the unused Revolving Loan Commitment.

NOTE B—Net Income per Common Share

        The following tables reconcile income (numerator) and shares (denominator) used in the computations of net income per common share (in thousands, except per share data):



 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 Three Months
Ended
March 31,
 


 2007 2008 2007 2008 
 2008 2009 

Numerator:

Numerator:

 

Numerator:

 

Net income

Net income

 $25,064 $23,489 $62,857 $62,621 

Net income

 $17,244 $13,560 
               

Denominator:

Denominator:

 

Denominator:

 

Weighted average number of common shares outstanding—basic

Weighted average number of common shares outstanding—basic

 39,193 40,272 38,759 39,991 

Weighted average number of common shares outstanding—basic

 39,736 36,208 

Common stock equivalents—stock options

 457 286 642 299 

Common stock equivalents—stock options

 394 86 

Common stock equivalents—warrants

 159 144 165 144 

Common stock equivalents—warrants

 167 87 

Common stock equivalents—restricted stock

 6 12 57 8 

Common stock equivalents—restricted stock

 7 5 

Common stock equivalents—restricted stock units

 34 8 31 15 

Common stock equivalents—restricted stock units

 36  

Common stock equivalents—employee stock purchase plan

     

Common stock equivalents—employee stock purchase plan

   
               

Weighted average number of common shares outstanding—diluted

Weighted average number of common shares outstanding—diluted

 39,849 40,722 39,654 40,457 

Weighted average number of common shares outstanding—diluted

 40,340 36,386 
               

Net income per common share—basic

Net income per common share—basic

 $0.64 $0.58 $1.62 $1.57 

Net income per common share—basic

 $0.43 $0.37 
               

Net income per common share—diluted

Net income per common share—diluted

 $0.63 $0.58 $1.59 $1.55 

Net income per common share—diluted

 $0.43 $0.37 
               

        The weighted average number of common shares outstanding for the three and nine months ended September 30, 2007March 31, 2008 and 20082009 was calculated using outstanding shares of the Company's Ordinary Common Stock. Common stock equivalents included in the calculation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2007March 31, 2008 and 20082009 represent stock options to purchase shares of the Company's Ordinary Common Stock, restricted stock awards and restricted stock units, stock to be purchased under the Employee Stock Purchase Plan and shares of Ordinary Common Stock related to certain warrants issued on January 5, 2004.


Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE B—Net Income per Common Share (Continued)

        For the three months ended March 31, 2009, the Company had additional potential dilutive securities outstanding representing 4.3 million options, 0.3 million restricted stock awards and 0.3 million restricted stock units that were not included in the computation of dilutive securities because they were anti-dilutive for the period. Had these shares not been anti-dilutive, all of these shares would not have been included in the net income per common share calculation as the Company uses the treasury stock method of calculating diluted shares.

NOTE C—Business Segment Information

        The accounting policies of the Company's segments are the same as those described in Note A—"General." The Company evaluates performance of its segments based on profit or loss from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes and minority interest ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Intersegment sales and transfers are not significant.



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE C—Business Segment Information (Continued)

        The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Three Months Ended September 30, 2007

                   
 

Net revenue

 $191,407 $249,510 $72,054 $45,105 $ $558,076 
 

Cost of care

  (91,769) (223,888) (53,351)     (369,008)
 

Cost of goods sold

        (37,341)   (37,341)
 

Direct service costs

  (39,307) (14,468) (14,097) (5,507)   (73,379)
 

Other operating expenses

          (29,089) (29,089)
 

Stock compensation expense(1)

  534  313  662  2,330  4,333  8,172 
              
 

Segment profit (loss)

 $60,865 $11,467 $5,268 $4,587 $(24,756)$57,431 
              
 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and
Other
 Consolidated 

Three Months Ended March 31, 2008

                   
 

Net revenue

 $159,603 $358,238 $75,499 $56,950 $ $650,290 
 

Cost of care

  (81,573) (323,174) (49,327)     (454,074)
 

Cost of goods sold

        (46,824)   (46,824)
 

Direct service costs

  (37,425) (16,623) (13,100) (5,920)   (73,068)
 

Other operating expenses

          (36,680) (36,680)
 

Stock compensation expense(1)

  423  174  505  2,104  8,812  12,018 
              
 

Segment profit (loss)

 $41,028 $18,615 $13,577 $6,310 $(27,868)$51,662 
              

 

 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Three Months Ended September 30, 2008

                   
 

Net revenue

 $163,240 $363,798 $72,692 $56,732 $ $656,462 
 

Cost of care

  (85,867) (320,479) (50,238)     (456,584)
 

Cost of goods sold

        (44,281)   (44,281)
 

Direct service costs

  (38,018) (17,668) (14,104) (6,713)��  (76,503)
 

Other operating expenses

          (29,376) (29,376)
 

Stock compensation expense(1)

  424  231  452  2,325  4,400  7,832 
              
 

Segment profit (loss)

 $39,779 $25,882 $8,802 $8,063 $(24,976)$57,550 
              


 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Nine Months Ended September 30, 2007

                   
 

Net revenue

 $590,260 $675,703 $101,245 $130,740 $ $1,497,948 
 

Cost of care

  (298,938) (598,451) (59,656)     (957,045)
 

Cost of goods sold

        (108,052)   (108,052)
 

Direct service costs

  (123,044) (35,015) (36,320) (15,733)   (210,112)
 

Other operating expenses

          (88,370) (88,370)
 

Stock compensation expense(1)

  1,695  770  1,670  6,483  12,044  22,662 
              
 

Segment profit (loss)

 $169,973 $43,007 $6,939 $13,438 $(76,326)$157,031 
              


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE C—Business Segment Information (Continued)


 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Nine Months Ended September 30, 2008

                   
 

Net revenue

 $486,792 $1,084,808 $223,890 $168,120 $ $1,963,610 
 

Cost of care

  (252,569) (963,374) (152,805)     (1,368,748)
 

Cost of goods sold

        (134,518)   (134,518)
 

Direct service costs

  (113,588) (51,135) (41,408) (18,764)   (224,895)
 

Other operating expenses

          (97,215) (97,215)
 

Stock compensation expense(1)

  1,097  598  1,096  6,445  17,113  26,349 
              
 

Segment profit (loss)

 $121,732 $70,897 $30,773 $21,283 $(80,102)$164,583 
              
 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and
Other
 Consolidated 

Three Months Ended March 31, 2009

                   
 

Net revenue

 $158,753 $321,860 $73,559 $65,343 $ $619,515 
 

Cost of care

  (89,786) (292,146) (49,786)     (431,718)
 

Cost of goods sold

        (52,072)   (52,072)
 

Direct service costs

  (38,525) (17,296) (13,038) (6,394)   (75,253)
 

Other operating expenses

          (27,811) (27,811)
 

Stock compensation expense(1)

  332  235  370  2,082  3,413  6,432 
              
 

Segment profit (loss)

 $30,774 $12,653 $11,105 $8,959 $(24,398)$39,093 
              

(1)
Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

Table of Contents


MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2009

(Unaudited)

NOTE C—Business Segment Information (Continued)

        The following table reconciles Segment Profit to consolidated income from continuing operations before income taxes and minority interest (in thousands):



 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 Three Months Ended
March 31,
 


 2007 2008 2007 2008 
 2008 2009 

Segment profit

Segment profit

 $57,431 $57,550 $157,031 $164,583 

Segment profit

 $51,662 $39,093 

Stock compensation expense

Stock compensation expense

 (8,172) (7,832) (22,662) (26,349)

Stock compensation expense

 (12,018) (6,432)

Depreciation and amortization

Depreciation and amortization

 (14,393) (16,086) (41,550) (44,983)

Depreciation and amortization

 (14,374) (11,043)

Interest expense

Interest expense

 (1,571) (592) (5,027) (2,824)

Interest expense

 (1,215) (427)

Interest income

Interest income

 6,434 4,127 17,140 13,336 

Interest income

 5,493 2,311 
               

Income from continuing operations before income taxes and minority interest

 $39,729 $37,167 $104,932 $103,763 

Income from continuing operations before income taxes

 $29,548 $23,502 
               

NOTE D—Commitments and Contingencies

Legal

        The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense. The Company is also subject to or party to certain class actions, litigation and claims relating to its operations and business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes



MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2008

(Unaudited)

NOTE D—Commitments and Contingencies (Continued)


that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

Stock Repurchase

        On July 30, 2008 the Company's board of directors approved a stock repurchase plan which authorizes the Company to purchase up to $200 million of its outstanding common stock through January 31, 2010. Stock repurchases under the program may be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deems appropriate. The stock repurchase program may be limited or terminated at any time without prior notice. Pursuant to this program, the Company made open market purchases of 394,7111,799,933 shares of the Company's common stock at an average share price of $42.22$34.32 per share for an aggregate cost of $16.7$61.8 million (excluding broker commissions) during the three months ended September 30, 2008.March 31, 2009. As of September 30, 2008, the Company has recorded a liability inMarch 31, 2009, the amount of $3.2 million for stock repurchases for which cash settledthat remained under the program was $2.2 million and such remaining repurchases were made during the period subsequent to such date.March 31, 2009, completing the repurchase program as of April 7, 2009.


Table of Contents

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations.

        The following discussion and analysis of the financial condition and results of operations of Magellan Health Services, Inc. ("Magellan"), and its majority-owned subsidiaries and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company") should be read together with the Condensed Consolidated Financial Statements and the notes to the Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-K for the year ended December 31, 2007,2008, which was filed with the Securities and Exchange Commission ("SEC") on February 29, 2008.27, 2009.

Forward-Looking Statements

        This Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Although the Company believes that its plans, intentions and expectations as reflected in such forward-looking statements are reasonable, it can give no assurance that such plans, intentions or expectations will be achieved. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include:



Table of Contents

        Further discussion of factors currently known to management that could cause actual results to differ materially from those in forward-looking statements is set forth under the heading "Risk Factors" in Item 1A of Magellan's Annual Report on Form 10-K for the year ended December 31, 2007 and Part II, Item 1A of this Form 10-Q.2008. When used in this Quarterly Report on Form 10-Q, the words "estimate," "anticipate," "expect," "believe," "should," and similar expressions are intended to be forward-looking statements. Magellan undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.

Business Overview

        The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. During 2006, the Company expanded into radiology benefits management and specialty pharmaceutical management as a result of certain acquisitions. The Company provides services to health plans, insurance companies, corporations, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

        Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide, or own any provider of, treatment services except as relates to the Company's contract to provide managed behavioral healthcare services to Medicaid recipients and other beneficiaries of the Maricopa County Regional Behavioral Health Authority (the "Maricopa Contract"). Under the Maricopa Contract, effective August 31, 2007 the Company was required to assume the operations of twenty-four behavioral health direct care facilities for a transitional period and to divest itself of these facilities over a two year period. During AugustMarch 2009, the Company began the operation of two additional behavioral health direct care facilities. At various dates in 2008 and October 2008,2009, the Company entered into agreements with twothree separate Provider


Table of Contents


Network Organizations ("PNOs") which will result into transition 20 of the transition of thirteen of such26 behavioral health direct care facilities to the PNOs over various datesdates. Fourteen of such direct care facilities have been transitioned through FebruaryApril 2009 and the Company expects to divest itself of the remainder of these facilities before August 31, 2009.

        The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing



treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

        The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

        Commercial.    The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations and governmental agencies, and labor unions. Commercial's managed behavioral healthcare contracts encompass either risk-based, or ASO arrangements or both. This segment contains the operating segments previously defined as the Managed Behavioral Healthcare Health Plan Segment ("Health Plan") and the Managed Behavioral Healthcare Employer segment ("Employer"). Prior period balances have been reclassified to reflect this change. The Company now considers Commercial as one segment and it is managed as such.EAP arrangements. As of September 30, 2008,March 31, 2009, Commercial's covered lives were 4.14.0 million, 14.713.7 million and 20.620.8 million for risk-based, EAP and ASO products, respectively. For the ninethree months ended September 30, 2008,March 31, 2009, Commercial's revenue was $311.9$100.9 million, $79.9$26.2 million and $95.0$31.7 million for risk-based, EAP and ASO products, respectively.

        Public Sector.    The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects managed behavioral healthcare services provided to Medicaid recipients under contracts with state and local governmental agencies. Public Sector contracts encompass either risk-based or ASO arrangements. As of September 30, 2008,March 31, 2009, Public Sector's covered lives were 2.21.4 million and 0.20.3 million for risk-based and ASO products, respectively. For the ninethree months ended September 30, 2008,March 31, 2009, Public Sector's revenue was $1.1 billion$320.3 million and $3.7$1.6 million for risk-based and ASO products, respectively.

Radiology Benefits Management.Management

        The Company's Radiology Benefits Management segment generally reflects the management of the delivery of diagnostic imaging services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicaid and Medicare members of the health plan. The Company also has a Medicaid contract with a state agency.members. The Company has bid and may bid in the future on contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company has won one state Medicaid contract, last year, which was implemented in July 2008. The Company offers its radiology benefits management services through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services, and through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services. The Company's first two risk-based radiology benefits management contracts became effective June 1, 2007 and July 1, 2007. As of September 30, 2008,March 31, 2009, covered lives for Radiology Benefits Management were 2.62.4 million and 15.514.9 million for risk-based and ASO products, respectively. For the ninethree months ended September 30, 2008,March 31, 2009, revenue for Radiology Benefits Management was $180.1$60.0 million and $43.8$13.6 million for risk-based and ASO products, respectively.


Table of Contents


Specialty Pharmaceutical Management.Management

        The Company's Specialty Pharmaceutical Management segment generally reflects the management of specialty drugs used in the treatment of cancer, multiple sclerosis, hemophilia, infertility, rheumatoid arthritis, chronic forms of hepatitis and other diseases. Specialty pharmaceutical drugs represent high-cost injectible, infused, oral, or inhaled drugs which



traditional retail pharmacies typicallyoften do not supply due to their high cost, sensitive handling, and storage needs. The Company's specialty pharmaceutical management services are provided under contracts with managed care companies, health insurers and other health plans for some or all of their commercial, Medicare and Medicaid members. The Company's specialty pharmaceutical services include (i) contracting and formulary optimization on behalf of health plans and pharmaceutical manufacturers; (ii) distributing specialty pharmaceutical drugs on behalf of health plans, (ii) administering on behalf of health plans rebate agreements between health plans and pharmaceutical manufacturers, andplans; (iii) providing strategic consulting services to health plans and pharmaceutical manufacturers.manufacturers; and (iv) providing oncology benefits management services to health plans. The Company's Specialty Pharmaceutical Management segment had contracts with 3140 health plans as of September 30, 2008.March 31, 2009.

Corporate and Other.Other

        This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

Significant Customers

        The Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the three months ended March 31, 2008 and 2009. In addition to the Maricopa Contract, the Company's contractscontract with the State of Tennessee's TennCare program ("TennCare") generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the ninethree months ended September 30, 2007. In addition to TennCare, the Company's Maricopa Contract generated net revenues that exceeded, in the aggregate, ten percent of net revenues for the consolidated Company for the nine months ended September 30,March 31, 2008. The Company also has a significant concentration of business from contracts with subsidiaries of WellPoint, Inc. ("WellPoint") and from contracts with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program.

        The Maricopa Contract, which began September 1, 2007 and which extends through June 30, 2010, generated net revenues of $48.1$149.5 million and $455.5$168.5 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively.

        The Company provides managed behavioral healthcare services for TennCare through contracts that extend through various dates.        The TennCare program is divided into three regions, and through March 31, 2007 the Company's TennCare contracts encompassed all of the TennCare membership for all three regions. As of April 1, 2007 substantially all of the membership in the Middle Grand Region was re-assigned to managed care companies in accordance with contract awards by TennCare pursuant to its request for proposals for the management of the integrated delivery of behavioral and physical medical care to the region. Substantially all of the membership in the West Grand and East Grand Regions willwas similarly be re-assigned to managed care companies in accordance with contract awards by TennCare effective November 1, 2008 and January 1, 2009, respectively. The Company continues to manage behavioral healthcare services for children enrolled in TennCare Select High, statewide, as well as for certain out-of-state TennCare members pursuant to contracts that extend through June 30, 2009. The Company recorded net revenues of $245.2$70.8 million and $217.1$12.8 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively, from its TennCare contracts. The portion


Table of the total net revenues associated with the programs for children and out-of-state members referred to above was $33.8 million and $34.2 million for the nine months ended September 30, 2007 and 2008, respectively.Contents

        Total net revenues from the Company's contracts with WellPoint were $155.7$51.6 million and $145.7$44.0 million during the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively, including radiology benefits management revenue of $44.7$42.0 million and $124.7$40.6 million, respectively. One of the Company's managed behavioral healthcare contracts with WellPoint was terminated by WellPoint effective March 31, 2007, and generated net revenues of $26.0 million during 2007. A second managed behavioral healthcare contract with WellPoint expired December 31, 2007 and generated net revenues of $63.9 million during the nine months ended September 30, 2007.


        In July 2007, WellPoint acquired a radiology benefits management company, and has expressed its intent to in-source all of its radiology benefits management contracts when such contracts expire. The Company hashad several radiology benefits management contracts with WellPoint including one that converted from an ASO arrangement to a risk arrangement effective July 1, 2007. Such risk contract originally had a three-year term through June 30, 2010, and cannot be terminated early, except for cause, as defined in the agreement. The term of this risk contract has been extended through December 31, 2010. The Company's other radiology benefits management ASO contracts with WellPoint generated $10.8$4.6 million of net revenues for the ninethree months ended September 30, 2008. Substantially all of this revenue relates toMarch 31, 2008, and these ASO contracts that have terms throughterminated at various dates in 2008.

        Net revenues from the Pennsylvania Counties in the aggregate totaled $198.5$71.3 million and $216.7$74.8 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively.

        WellPoint generated greater than ten percent of net revenues for the Commercial segment for the nine months ended September 30, 2007. Two other customers generated greater than ten percent of Commercial net revenues for the ninethree months ended September 30, 2007March 31, 2008 and 2008.2009. The first customer has a contract that extends through December 31, 20102012 and generated net revenues of $129.3$49.6 million and $159.4$57.3 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively. The second customer has a contract that extends through June 30, 2009 and generated net revenues of $66.8$22.1 million and $67.7$21.9 million for the ninethree months ended SeptemberMarch 31, 2008 and 2009, respectively. On April 30, 20072009, the Company and 2008, respectively.this customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the third anniversary of the contract.

        In addition to the Maricopa Contract and TennCare, were the only customers withone other customer generated net revenues greater than ten percent of the net revenues for the Public Sector segment for the ninethree months ended September 30, 2008. For the nine months ended September 30, 2007, one customer other then TennCare generated greater than ten percent of the net revenues for the Public Sector segment for such period.March 31, 2008 and 2009. This customer has a contract that extends through June 30,December 31, 2009 and generated net revenues of $92.3$37.2 million and $106.0$36.0 million, respectively. Pursuant to an RFP process, the customer notified the Company of its intent to award the contract to provide servicing beyond December 31, 2009. The award is subject to the negotiation and execution of a contract between the Company and the customer. The proposed new contract will have a term of 2.5 years beginning on January 1, 2010 with options for the nine months ended September 30, 2007 and 2008, respectively.customer to extend the term of the contract for three one year terms.

        In addition to WellPoint, one other customer generated greater than ten percent of the net revenues for the Radiology Benefits Management segment for the ninethree months ended September 30, 2007March 31, 2008 and 2008.2009. This customer has a contract that extends through May 31, 2011 and generated net revenues of $34.5$24.9 million and $73.4$22.6 million for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively.

        Included in the Company's Specialty Pharmaceutical Management segment are fourfive customers that each exceeded ten percent of the net revenues for this segment for the ninethree months ended September 30, 2007. The fourMarch 31, 2008. Four of such customers generated $44.4$17.1 million, $25.5$13.6 million, $23.7$7.5 million, and $18.2$7.1 million of net revenues during the ninethree months ended September 30, 2007.March 31, 2008. The other contract generated net revenues of $7.2 million for the three months ended March 31, 2008, and this contract terminated as of December 31, 2008. For the ninethree months ended September 30, 2008, fiveMarch 31, 2009, four customers each exceeded ten percent of the net revenues for this segment. Four of such customers generated $52.9$20.2 million, $36.3$13.9 million, $21.1$9.3 million, and $20.2$7.3 million of net revenues during the ninethree months ended September 30, 2008.March 31, 2009. The otherpreviously mentioned contract that terminated as of December 31, 2008 generated net revenues for run-off activity of $21.1$6.6 million for the ninethree months ended September 30, 2008, and such customer has indicated that they do not intend to continue the contract inMarch 31, 2009.


Table of Contents

Off-Balance Sheet Arrangements

        The Company does not maintain any off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on the Company's finances that is material to investors.


Critical Accounting Policies and Estimates

        The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Except as noted below, the Company's critical accounting policies are summarized in the Company's Annual Report on Form 10-K, filed with the SEC on February 29, 2008.27, 2009.

Income Taxes

        The Company's effective income tax rate was 40.041.6 percent and 39.642.3 percent for the ninethree months ended September 30, 2007March 31, 2008 and 2008,2009, respectively. This rate differsThese rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes.

        The Company files a consolidated federal income tax return for the Company and its eighty-percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various statestates and local jurisdictions. TheWith few exceptions, the Company is no longer subject to additional federal income taxes for any tax year ended prior to 2005, although the NOLs from such prior years remain subject to examination by the IRS. With few exceptions, the Company is also no longer subject to additional state or local income tax examinations by tax authorities for years ended prior to December 31, 2005. The statute of limitations regarding the assessment of federal and most state and local income taxes for the year ended December 31, 2005 will expire during 2009.

        Prior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the Bankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to 2004 or, in a few jurisdictions, for the 2004Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax year as well.

        The statutes of limitation regarding substantially all of the remaining unrecognized state and local tax benefits for 2004 will expire during the fourth quarter of 2008.expense. As a result the Company anticipates that up to $4.0 million of grossimplementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits (excluding interest costs) recordedwill be reflected as of September 30, 2008 could be reversed during the fourth quarter, substantially all of which would be recorded (net of the related indirect tax benefits) as a reductionreductions to income tax expense.expense, even if related to years prior to the Company's reorganization.


Table of Contents

Results of Operations

        The Company evaluates performance of its segments based on profit or loss from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes and minority interest ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Intersegment sales and transfers are not significant. The Company's segments are defined above.

        The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Three Months Ended September 30, 2007

                   
 

Net revenue

 $191,407 $249,510 $72,054 $45,105 $ $558,076 
 

Cost of care

  (91,769) (223,888) (53,351)     (369,008)
 

Cost of goods sold

        (37,341)   (37,341)
 

Direct service costs

  (39,307) (14,468) (14,097) (5,507)   (73,379)
 

Other operating expenses

          (29,089) (29,089)
 

Stock compensation expense(1)

  534  313  662  2,330  4,333  8,172 
              
 

Segment profit (loss)

 $60,865 $11,467 $5,268 $4,587 $(24,756)$57,431 
              


 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Three Months Ended September 30, 2008

                   
 

Net revenue

 $163,240 $363,798 $72,692 $56,732 $ $656,462 
 

Cost of care

  (85,867) (320,479) (50,238)     (456,584)
 

Cost of goods sold

        (44,281)   (44,281)
 

Direct service costs

  (38,018) (17,668) (14,104) (6,713)   (76,503)
 

Other operating expenses

          (29,376) (29,376)
 

Stock compensation expense(1)

  424  231  452  2,325  4,400  7,832 
              
 

Segment profit (loss)

 $39,779 $25,882 $8,802 $8,063 $(24,976)$57,550 
              
 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and
Other
 Consolidated 

Three Months Ended March 31, 2008

                   
 

Net revenue

 $159,603 $358,238 $75,499 $56,950 $ $650,290 
 

Cost of care

  (81,573) (323,174) (49,327)     (454,074)
 

Cost of goods sold

        (46,824)   (46,824)
 

Direct service costs

  (37,425) (16,623) (13,100) (5,920)   (73,068)
 

Other operating expenses

          (36,680) (36,680)
 

Stock compensation expense(1)

  423  174  505  2,104  8,812  12,018 
              
 

Segment profit (loss)

 $41,028 $18,615 $13,577 $6,310 $(27,868)$51,662 
              

 

 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Nine Months Ended September 30, 2007

                   
 

Net revenue

 $590,260 $675,703 $101,245 $130,740 $ $1,497,948 
 

Cost of care

  (298,938) (598,451) (59,656)     (957,045)
 

Cost of goods sold

        (108,052)   (108,052)
 

Direct service costs

  (123,044) (35,015) (36,320) (15,733)   (210,112)
 

Other operating expenses

          (88,370) (88,370)
 

Stock compensation expense(1)

  1,695  770  1,670  6,483  12,044  22,662 
              
 

Segment profit (loss)

 $169,973 $43,007 $6,939 $13,438 $(76,326)$157,031 
              


 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and Other
 Consolidated 

Nine Months Ended September 30, 2008

                   
 

Net revenue

 $486,792 $1,084,808 $223,890 $168,120 $ $1,963,610 
 

Cost of care

  (252,569) (963,374) (152,805)     (1,368,748)
 

Cost of goods sold

        (134,518)   (134,518)
 

Direct service costs

  (113,588) (51,135) (41,408) (18,764)   (224,895)
 

Other operating expenses

          (97,215) (97,215)
 

Stock compensation expense(1)

  1,097  598  1,096  6,445  17,113  26,349 
              
 

Segment profit (loss)

 $121,732 $70,897 $30,773 $21,283 $(80,102)$164,583 
              
 
 Commercial Public
Sector
 Radiology
Benefits
Management
 Specialty
Pharmaceutical
Management
 Corporate
and
Other
 Consolidated 

Three Months Ended March 31, 2009

                   
 

Net revenue

 $158,753 $321,860 $73,559 $65,343 $ $619,515 
 

Cost of care

  (89,786) (292,146) (49,786)     (431,718)
 

Cost of goods sold

        (52,072)   (52,072)
 

Direct service costs

  (38,525) (17,296) (13,038) (6,394)   (75,253)
 

Other operating expenses

          (27,811) (27,811)
 

Stock compensation expense(1)

  332  235  370  2,082  3,413  6,432 
              
 

Segment profit (loss)

 $30,774 $12,653 $11,105 $8,959 $(24,398)$39,093 
              

(1)
Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

        The following table reconciles Segment Profit to consolidated income from continuing operations before income taxes and minority interest (in thousands):



 Three Months Ended
September 30,
 Nine Months Ended
September 30,
 
 Three Months Ended
March 31,
 


 2007 2008 2007 2008 
 2008 2009 

Segment profit

Segment profit

 $57,431 $57,550 $157,031 $164,583 

Segment profit

 $51,662 $39,093 

Stock compensation expense

Stock compensation expense

 (8,172) (7,832) (22,662) (26,349)

Stock compensation expense

 (12,018) (6,432)

Depreciation and amortization

Depreciation and amortization

 (14,393) (16,086) (41,550) (44,983)

Depreciation and amortization

 (14,374) (11,043)

Interest expense

Interest expense

 (1,571) (592) (5,027) (2,824)

Interest expense

 (1,215) (427)

Interest income

Interest income

 6,434 4,127 17,140 13,336 

Interest income

 5,493 2,311 
               

Income from continuing operations before income taxes and minority interest

 $39,729 $37,167 $104,932 $103,763 

Income from continuing operations before income taxes

 $29,548 $23,502 
               

Table of Contents

Quarter ended September 30, 2008March 31, 2009 ("Current Year Quarter"), compared to the quarter ended September 30, 2007March 31, 2008 ("Prior Year Quarter")

Commercial

Net Revenue

        Net revenue related to Commercial decreased by 14.70.5 percent or $28.2$0.9 million from the Prior Year Quarter to the Current Year Quarter. The decrease in revenue is mainly due to terminated contracts of $43.9$9.5 million and favorable retroactive rate and membership adjustments of $3.9 million recorded in the Prior Year Quarter, which decrease wasdecreases were partially offset by increased membership from existing customers of $8.5$7.3 million, favorable retroactive membership and rate changesadjustments of $4.8$0.8 million recorded in the Current Year Quarter, revenue from new contracts implemented after (or during) the Prior Year Quarter of $1.1$0.8 million, favorable rate changes of $0.6 million, and other net favorable variances of $1.3$3.0 million.

Cost of Care

        Cost of care decreasedincreased by 6.410.1 percent or $5.9$8.2 million from the Prior Year Quarter to the Current Year Quarter. The decreaseincrease in cost of care is primarily due to terminated contractsincreased membership from existing customers of $24.7$4.9 million, and favorableunfavorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of $3.5 million, which decreases were partially offset by favorable prior period medical claims development recorded in the Prior Year Quarter of $6.0 million, increased membership from existing customers of $5.4$1.5 million, unfavorable prior period medical claims development recorded in the Current Year Quarter of $0.2$0.4 million, and care trends and other net variances of $10.7$13.2 million, which increases were partially offset by terminated contracts of $6.2 million and unfavorable prior period medical claims development recorded in the Prior Year Quarter of $5.6 million. Cost of care increased as a percentage of risk revenue (excluding EAP business) from 66.473.8 percent in the Prior Year Quarter to 75.681.4 percent in the Current Year Quarter, mainly due to unfavorable care trend in excess of rate changes,trends, out of period care development, and changes in business mix.

Direct Service Costs

        Direct service costs decreasedincreased by 3.32.9 percent or $1.3$1.1 million from the Prior Year Quarter to the Current Year Quarter. The decreaseincrease in direct service costs is mainly attributable to terminated contracts.cost incurred to claims processing costs. Direct service costs increased as a percentage of revenue from 20.523.4 percent in the Prior Year Quarter to 23.324.3 percent in the Current Year Quarter,Quarter. The increase in the percentage of direct service costs in relation to revenue is mainly due to changes in business mix.

Public Sector

Net Revenue

        Net revenue related to Public Sector increaseddecreased by 45.810.2 percent or $114.3$36.4 million from the Prior Year Quarter to the Current Year Quarter. This increasedecrease is primarily due to higher revenue from the Maricopa Contract which was implemented during the Prior Year Quarternet impact of $104.2 million, net favorable rate changes of $8.3 million, and netterminated contracts offset by increased membership from existing customers of $2.8$39.2 million, which increases were partially offset byfavorable retroactive rate changes recorded in the Prior Year Quarter of $3.6 million, unfavorable retroactive rate and membership changes recorded in the Current Year Quarter of $2.1 million, and other net unfavorable variances of $1.0$0.2 million, which decreases was partially offset by net favorable rate and contract funding changes of $8.7 million.

Cost of Care

        Cost of care increaseddecreased by 43.19.6 percent or $96.6$31.0 million from the Prior Year Quarter to the Current Year Quarter. This increasedecrease is primarily due to higher care associated with terminated contracts offset by increased membership from existing customers of $32.4 million, favorable medical claims development for the Maricopa Contract,Prior Year Quarter which was implemented duringrecorded after the Prior Year Quarter of $95.3$5.5 million, care


Table of Contents


associated with retroactive rate changes for contracts with minimum cost of care requirements of $2.5 million, increased membership from existing customers of $2.0 million, and care trends and other net variances of $1.4 million, which increases were partially offset by favorable prior period medical claims development recorded in the CurrentPrior Year Quarter of $3.4$3.1 million, and unfavorable prior period medical claims development recorded in the Prior Year Quarter of $1.2 million, which decreases were partially offset by unfavorable prior period medical claims development recorded in the Current Year Quarter of $3.1 million, care associated with rate changes for contracts with minimum cost of care requirements of $3.9 million, and care trends and other net unfavorable variances of $4.2 million. Cost of care decreasedincreased as a percentage of risk revenue from 90.190.5 percent in the Prior Year Quarter to 88.491.2 percent in the Current Year Quarter mainly due to rate changes in excess ofbusiness mix and net unfavorable care trend, out of period care development and changes in business mix.


development.

Direct Service Costs

        Direct service costs increased by 22.14.0 percent or $3.2$0.7 million from the Prior Year Quarter to the Current Year Quarter. The increase in direct service costs is primarily due to the Current Year Quarter including a full quarter ofincreased costs forassociated with the Maricopa Contract. Direct service costs decreasedincreased as a percentage of revenue from 5.84.6 percent for the Prior Year Quarter, partially offset by costs from terminated contracts to 4.95.4 percent in the Current Year Quarter mainly due to business mix.

Radiology Benefits Management

Net Revenue

        Net revenue related to Radiology Benefits Management increaseddecreased by 0.92.6 percent or $0.6 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to favorable rate changes of $5.1 million and revenue from new customers implemented after (or during) the Prior Year Quarter of $2.7 million, which increases were partially offset by revenue reductions associated with favorable care development and care trends of $0.8 million, net decreased membership from existing customers of $1.4 million (including a net decrease in risk membership of $3.6 million), a net decrease in performance related revenue of $1.2 million, terminated contracts of $1.1 million, and other net unfavorable variances of $2.7 million.

Cost of Care

        Cost of care decreased by 5.8 percent or $3.1$1.9 million from the Prior Year Quarter to the Current Year Quarter. This decrease is primarily due to the net decrease indecreased membership from existing risk customers of $3.4$5.8 million, terminated contracts of $3.2 million, and favorable prior period medical claims development recorded in the Current Year Quarterother net decreases of $3.1$1.0 million, which decreases were partially offset by favorable rate changes of $8.1 million (including $1.4 million of retroactive rate changes recorded in the Current Year Quarter).

Cost of Care

        Cost of care associated with new customers implemented after (or during)increased by 0.9 percent or $0.5 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily attributed to favorable prior period medical claims development of $1.6$1.1 million unfavorablerecorded in the Prior Year Quarter and care trends and other net variances of $7.3 million, which increases were partially offset by decreased membership from existing customers of $4.9 million, favorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of $0.8$2.0 million, and care trends and other net unfavorable variancesfavorable prior period medical claims development recorded in the Current Year Quarter of $1.0 million. Cost of care decreasedincreased as a percentage of risk revenue from 92.782.6 percent in the Prior Year Quarter to 85.483.0 percent in the Current Year Quarter mainly due to rate changes in excess of care trend, favorable care development and business mix.trends.

Direct Service Costs

        CurrentDirect service costs decreased by 0.5 percent or $0.1 million from the Prior Year Quarter direct service costs are consistent withto the PriorCurrent Year Quarter. As a percentage of revenue, direct service costs decreasedincreased from 19.617.4 percent in the Prior Year Quarter to 19.417.7 percent in the Current Year Quarter, mainly due to business mix.

Specialty Pharmaceutical Management

Net Revenue

        Net revenue related to Specialty Pharmaceutical Management increased by 25.814.7 percent or $11.6$8.4 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to net increased distribution activity from new and existing customers of $8.0$9.4 million, and increased consulting and rebate revenue of $3.7$1.6 million (including $0.8 million of retroactive rebate revenue recorded in the Current Year Quarter), which increases were partially offset by net unfavorable variancesterminated distribution contracts of $0.1$2.6 million.


Table of Contents

Cost of Goods Sold

        Cost of goods sold increased by 18.611.2 percent or $6.9$5.2 million from the Prior Year Quarter to the Current Year Quarter,Quarter. This increase is primarily due to net increased distribution activity from new and existing



customers. customers of $8.6 million, which increase was partially offset by terminated contracts of $2.4 million and other net favorable variances of $1.0 million. As a percentage of the portion of net revenue that relates to distribution activity, cost of goods sold decreased from 93.493.6 percent in the Prior Year Quarter to 92.891.9 percent in the Current Year Quarter, mainly due to business mix.

Direct Service Costs

        Direct service costs increased by 21.98.0 percent or $1.2$0.5 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to expenses required to support the aforementioned increases to revenue. As a percentage of revenue, direct service costs decreased from 12.210.4 percent in the Prior Year Quarter to 11.89.8 percent in the Current Year Quarter, mainly due to the increased distribution revenue.Quarter.

Corporate and Other

Other Operating Expenses

        Other operating expenses related to the Corporate and Other Segment increaseddecreased by 1.024.2 percent or $0.3$8.9 million from the Prior Year Quarter to the Current Year Quarter. The increase isdecrease results primarily duefrom prior year expenses incurred pursuant to the impactformer Chief Executive Officer's employment agreement in relation to his service to the Company ending of cost inflation,$10.1 million (including $5.4 million of stock compensation expense related to the acceleration of vesting for certain equity awards), which decrease was partially offset by improved productivity.other net unfavorable variances of $1.2 million. As a percentage of total net revenue, other operating expenses decreased from 5.25.6 percent for the Prior Year Quarter to 4.5 percent for the Current Year Quarter, primarily due to business mix andprior year expenses incurred pursuant to the increased revenue from the Maricopa Contract.former Chief Executive Officer's employment agreement.

Depreciation and Amortization

        Depreciation and amortization expense increaseddecreased by 11.823.2 percent or $1.7$3.3 million from the Prior Year Quarter to the Current Year Quarter, primarily due to asset additions after (or during) the Prior Year Quarter, inclusive of assets related to the Maricopa Contract, partially offset by a decrease in amortization expense due to an intangible asset whichthat became fully amortized in the prior year.depreciated as of December 31, 2008.

Interest Expense

        Interest expense decreased by 62.364.9 percent or $1.0$0.8 million from the Prior Year Quarter to the Current Year Quarter, mainly due to reductions in outstanding debt balances as a result of debtscheduled payments and lower interest rates.rates in the Current Year Quarter.

Interest Income

        Interest income decreased by $2.3$3.2 million from the Prior Year Quarter to the Current Year Quarter, mainly due to lower yields.

Income Taxes

        The Company's effective income tax rate was 37.041.6 percent in the Prior Year Quarter which is consistent withand 42.3 percent in the Current Year Quarter. The Prior Year Quarter and Current Year Quarter effective income tax rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income.


Nine months ended September 30, 2008 ("Current Year Period"), compared to the nine months ended September 30, 2007 ("Prior Year Period")

Commercial

Net Revenue

        Net revenue related to Commercial decreased by 17.5 percent or $103.5 million from the Prior Year Period to the Current Year Period. The decrease in revenue is mainly due to terminated contractsTable of $148.2 million and net favorable retroactive membership adjustments of $2.2 million recorded in the Prior Year Period, which decreases were partially offset by increased membership from existing customers of $22.7 million, favorable rate changes of $13.5 million, favorable retroactive membership and rate adjustments of $4.6 million recorded in the Current Year Period, revenue from new contracts implemented after (or during) the Prior Year Period of $4.2 million, and other net favorable variances of $1.9 million.

Cost of CareContents

        Cost of care decreased by 15.5 percent or $46.4 million from the Prior Year Period to the Current Year Period. The decrease in cost of care is primarily due to terminated contracts of $91.5 million and favorable medical claims development for the Prior Year Period which was recorded after the Prior Year Period of $1.1 million, which decreases were partially offset by increased membership from existing customers of $12.6 million, favorable prior period medical claims development recorded in the Prior Year Period of $6.9 million, unfavorable prior period medical claims development recorded in the Current Year Period of $4.4 million, and care trends and other net variances of $22.3 million. Cost of care increased as a percentage of risk revenue (excluding EAP business) from 69.5 percent in the Prior Year Period to 74.4 percent in the Current Year Period, mainly due to unfavorable care trends and care development.

Direct Service Costs

        Direct service costs decreased by 7.7 percent or $9.5 million from the Prior Year Period to the Current Year Period. The decrease in direct service costs is mainly attributable to terminated contracts. Direct service costs increased as a percentage of revenue from 20.8 percent in the Prior Year Period to 23.3 percent in the Current Year Period, mainly due to changes in business mix.

Public Sector

Net Revenue

        Net revenue related to Public Sector increased by 60.5 percent or $409.1 million from the Prior Year Period to the Current Year Period. This increase is primarily due to revenue from new customers implemented during the Prior Year Period of $413.4 million, net favorable rate changes of $26.4 million (including $3.6 million of retroactive rate changes recorded in the Current Year Period), and increased membership from existing customers of $3.8 million, which increases were partially offset by a net loss of membership in connection with the Middle Grand Region of TennCare of $32.2 million and other net unfavorable variances of $2.3 million.

Cost of Care

        Cost of care increased by 61.0 percent or $364.9 million from the Prior Year Period to the Current Year Period. This increase is primarily due to care associated with new customers of $380.1 million, care associated with rate changes for contracts with minimum cost of care requirements of $17.6 million (including $3.1 million of care recorded in the Current Year Period associated with retroactive rate changes), increased membership from existing customers of $1.7 million, and favorable



prior period medical claims development recorded in the Prior Year Period of $1.5 million, which increases were partially offset by the net loss of membership in connection with the Middle Grand Region of TennCare of $26.5 million, favorable prior period medical claims development recorded in the Current Year Period of $8.2 million, and care trends and other net favorable variances of $1.3 million. Cost of care increased as a percentage of risk revenue from 89.0 percent in the Prior Year Period to 89.1 percent in the Current Year Period mainly due to business mix.

Direct Service Costs

        Direct service costs increased by 46.0 percent or $16.1 million from the Prior Year Period to the Current Year Period. The increase in direct service costs is primarily due to costs associated with new business. Direct service costs decreased as a percentage of revenue from 5.2 percent for the Prior Year Period to 4.7 percent in the Current Year Period mainly due to business mix.

Radiology Benefits Management

Net Revenue

        Net revenue related to Radiology Benefits Management increased by 121.1 percent or $122.6 million from the Prior Year Period to the Current Year Period. This increase is primarily due to the conversion of an ASO contract to a risk contract of $75.0 million, revenue from new customers implemented after (or during) the Prior Year Period of $47.9 million, net increased membership from existing customers of $1.2 million (inclusive of a net decrease in risk membership of $5.1 million), and other net favorable variances of $1.6 million, which increases were partially offset by terminated contracts of $3.1 million.

Cost of Care

        Cost of care increased by $93.1 million from the Prior Year Period to the Current Year Period. This increase is primarily due to the conversion of an ASO contract to a risk contract of $62.6 million, care associated with new customers implemented after (or during) the Prior Year Period of $38.3 million, and unfavorable medical claims development for the Prior Year Period which was recorded after the Prior Year Period of $0.8 million, which increases were partially offset by favorable prior period medical claims development recorded in the Current Year Period of $1.9 million, decreased membership from existing risk customers of $4.8 million, and care trends and other net favorable variances of $1.9 million. Cost of care decreased as a percentage of risk revenue from 92.9 percent in the Prior Year Period to 84.9 percent in the Current Year Period mainly due to favorable care development and business mix.

Direct Service Costs

        Direct service costs increased by 14.0 percent or $5.1 million from the Prior Year Period to the Current Year Period. This increase is primarily attributed to additional costs incurred to support the new risk contract which was implemented in June 2007. As a percentage of revenue, direct service costs decreased from 35.9 percent in the Prior Year Period to 18.5 percent in the Current Year Period, mainly due to the additional revenue provided by the risk-based contracts in the Current Year Period.

Specialty Pharmaceutical Management

Net Revenue

        Net revenue related to Specialty Pharmaceutical Management increased by 28.6 percent or $37.4 million from the Prior Year Period to the Current Year Period. This increase is primarily due to net increased distribution activity from new and existing customers of $28.3 million, increased



consulting and rebate revenue of $8.7 million (including $0.5 million of retroactive rebate revenue recorded in the Current Year Period), and other net favorable variances of $0.4 million.

Cost of Goods Sold

        Cost of goods sold increased by 24.5 percent or $26.5 million from the Prior Year Period to the Current Year Period, primarily due to net increased distribution activity from new and existing customers. As a percentage of the portion of net revenue that relates to distribution activity, cost of goods sold increased from 92.7 percent in the Prior Year Period to 93.0 percent in the Current Year Period, mainly due to business mix.

Direct Service Costs

        Direct service costs increased by 19.3 percent or $3.0 million from the Prior Year Period to the Current Year Period. This increase is primarily due to expenses required to support the aforementioned increases to revenue. As a percentage of revenue, direct service costs decreased from 12.0 percent in the Prior Year Period to 11.2 percent in the Current Year Period, mainly due to increased distribution revenue.

Corporate and Other

Other Operating Expenses

        Other operating expenses related to the Corporate and Other Segment increased by 10.0 percent or $8.8 million from the Prior Year Period to the Current Year Period. The increase results primarily from current year expenses incurred pursuant to the former Chief Executive Officer's employment agreement in relation to his service to the Company ending of $10.1 million (includes $5.4 million of stock compensation expense related to the acceleration of vesting for certain equity awards), and net one-time expenses incurred in the Current Year Period of $2.7 million, which increases were partially offset by expenses in the Prior Year Period related to bid proposals of $2.5 million and other net favorable variances of $1.5 million. As a percentage of total net revenue, other operating expenses decreased from 5.9 percent for the Prior Year Period to 5.0 percent for the Current Year Period, primarily due to business mix and the increased revenue from the radiology risk contracts and the Maricopa Contract.

Depreciation and Amortization

        Depreciation and amortization expense increased by 8.3 percent or $3.4 million from the Prior Year Period to the Current Year Period, primarily due to asset additions after (or during) the Prior Year Period, inclusive of assets related to the Maricopa Contract, partially offset by a decrease in amortization expense due to an intangible asset which became fully amortized in the prior year.

Interest Expense

        Interest expense decreased by 43.8 percent or $2.2 million from the Prior Year Period to the Current Year Period, mainly due to reductions in outstanding debt balances as a result of debt payments and lower interest rates.

Interest Income

        Interest income decreased by $3.8 million from the Prior Year Period to the Current Year Period mainly due to lower yields.


Income Taxes

        The Company's effective income tax rate was 40.0 percent in the Prior Year Period and 39.6 percent in the Current Year Period. The Prior Year Period and Current Year Period effective income tax rates differ from the federal statutory income tax rate primarily due to state income taxes and permanent differences between book and tax income.

Outlook—Results of Operations

        The Company's Segment Profit and net income are subject to significant fluctuations from period to period. These fluctuations may result from a variety of factors such as those set forth under Item 2—"Forward-Looking Statements" as well as a variety of other factors including: (i) changes in utilization levels by enrolled members of the Company's risk-based contracts, including seasonal utilization patterns; (ii) contractual adjustments and settlements; (iii) retrospective membership adjustments; (iv) timing of implementation of new contracts, enrollment changes and contract terminations; (v) pricing adjustments upon contract renewals (and price competition in general); and (vi) changes in estimates regarding medical costs and incurred but not yet reported medical claims.

        Care Trends.    The Company expects that the Commercial care trend factorfactors for 20082009 for Commercial will be 57 to 79 percent, the Public Sector care trend factor for 2008 will be 3 to 5 percent, and the Radiology Benefits Management care trend for 2008 will be 1210 to 1513 percent.

        Interest Rate Risk.    Changes in interest rates affect interest income earned on the Company's cash equivalents and investments, as well as interest expense on variable interest rate borrowings under the Company's credit agreementfacility with Deutsche Bank AG and Citigroup Global Markets Inc. dated April 30, 2008 (the "New"2008 Credit Facility"). Based on the amount of cash equivalents and investments and the borrowing levels under the New2008 Credit Facility as of September 30, 2008,March 31, 2009, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.

Historical—Liquidity and Capital Resources

        Operating Activities.    The Company reported net cash provided by operating activities of $152.5$12.4 million and $236.8$58.6 million for the Prior Year PeriodQuarter and Current Year Period,Quarter, respectively. The $84.3$46.2 million increase in operating cash flows from the Prior Year Quarter to the Current Year Quarter is primarily dueattributable to the year-over-year increase of $114.6 million in the shift of restricted cash to restricted investments, with $11.4 million and $126.0which results in an operating cash flow source that is directly offset by an investing cash flow use. During the Prior Year Quarter, $10.9 million of restricted cash beingwas shifted to restricted investments as compared to the Current Year Quarter in thewhich $37.5 million of restricted cash was shifted to restricted investments, which results in a net increase in operating cash flows of $26.6 million. The Prior Year Period and Current Year Period, respectively,Quarter included restricted cash funding of $15.0 million for a risk radiology contract, the run-out of net contract liabilities associated with terminated Commercial contracts of $11.4 million and the increase in segment profit between periodsnet funding of $7.6 million.restricted cash of $10.6 million associated with the Company's regulated entities. Partially offsetting these items is the fundingdecrease in Segment Profit of $12.6 from the Prior Year Quarter and other net unfavorable variances of $4.8 million primarily associated with working capital changes.

        During the Current Year Quarter, the Company's restricted cash decreased $64.4 million. The change in restricted cash is attributable to the shift of $37.5 million in restricted cash to restricted investments, a reduction in restricted cash of $15.2$22.9 million duringassociated with the Current Year Period for a risk radiology contract,Company's regulated entities and other net decreases of $4.0 million. In regards to the increase between periods in the run-out of net contract liabilities for terminated contracts of $5.8 million, the net increase between periodsdecrease in restricted cash associated with the Company's regulated entities, of $6.9$24.0 million is offset by changes in other assets and liabilities, primarily medical claims payable and other medical liabilities, thus having no impact on operating cash flows. Partially offsetting these reductions is the net unfavorable itemsfunding of $10.0$1.1 million mainly due to timing andin additional working capital requirements to supportrestricted cash associated with the Company's growth.regulated entities.

        Investing Activities.    The Company utilized $31.8$8.0 million and $24.0$5.3 million during the Prior Year PeriodQuarter and Current Year Period,Quarter, respectively, for capital expenditures. The majority of the decrease in capital expenditures of $2.7 million is attributable to capital expenditures incurred during the Prior Year Quarter of $1.5 million associated with the Maricopa Contract. Most of the remainder of the


Table of Contents


capital expenditures for the Prior Year Quarter and the majority of capital expenditures for the Current Year Quarter related to management information systems and related equipment.

During the Prior Year Period,Quarter, the Company incurred capital expendituresreceived net cash of $12.4$18.1 million related tofrom the implementation and start-upnet maturity of the Maricopa County contract, with $7.0 million of this total attributable to fixed assets related to clinics that were purchased from Value Options."available for sale" investments. During the current year period, capital expenditures associated withCurrent Year Quarter, the Maricopa County contract totaled $4.9 million.

        The Company used net cash of $6.9$29.0 million and $252.7 million infor the Prior Year Period and Current Year Period, respectively,purchase of "available for thesale" investments. The net purchase of "available-for-sale" investments. The



Company's"available for sale" investments consistduring the Current Year Quarter is primarily attributable to the shift of U.S. government and agency securities, obligationsrestricted cash of government-sponsored enterprises, corporate debt securities, money market funds and certificates of deposit.$37.5 million to restricted investments, partially offset by matured unrestricted investments that were not reinvested.

        During the Prior Year Period and Current Year Period,Quarter, the Company made paymentsthe final working capital payment of $5.3 million and $0.4 million respectively, for the working capital received inrelated to the acquisition of ICORE Healthcare LLC ("ICORE"), with the payment made during the Current Year Period representing the final ICORE working capital payment.LLC.

        Financing Activities.    During the Prior Year Period,Quarter, the Company had debtrepaid $4.2 million of indebtedness outstanding under the Company's credit agreement with Deutsche Bank AG dated January 5, 2004, as amended (the "Credit Agreement") and made payments on capital lease paymentsobligations of $20.3$0.1 million. In addition, the Company received $26.7$4.0 million from the exercise of stock options and warrants and had other net financing related cash outflowsunfavorable items of $0.2$1.5 million.

        During the Current Year Period,Quarter, the Company had debt and capital lease paymentspaid $59.5 million for repurchase of $12.7 million.treasury stock under the Company's share repurchase program. In addition, the Company received $12.6$0.9 million from the exercise of stock options and warrants paid $13.5 million for the repurchase of treasury stock under the Company's share repurchase program and had other net financing related cash inflowsfavorable items of $4.1$0.7 million.

Outlook—Liquidity and Capital Resources

        Liquidity.    During 2008,2009, the Company expects to fund its estimated capital expenditures of $20 to $30 million with cash from operations. The Company estimates that it will spend approximately $6 million to $16 million of additional funds in 2008 for capital expenditures. The Company does not anticipate that it will need to draw on amounts available under the Revolving Loan borrowing of the New2009 Credit Facility (as defined below) for its operations, capital needs or debt service in 2008.2009. The Company also currently expects to have adequate liquidity to satisfy its existing financial commitments over the periods in which they will become due. The Company maintains its current investment strategy of investing in a diversified, high quality, liquid portfolio of investments and continues to closely monitor the situation in the financial and credit markets. The Company estimates that it has no risk of any material permanent loss on its investment portfolio; however, there can be no assurance that the Company will not experience any such losses in the future.

        Stock Repurchase.    On July 30, 2008 the Company's board of directors approved a stock repurchase plan which authorizes the Company to purchase up to $200 million of its outstanding common stock through January 31, 2010. Stock repurchases under the program may be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deems appropriate. The stock repurchase program may be limited or terminated at any time without prior notice. The Company expects to fund the stock repurchases using cash on hand. From July 1, 2008 through September 30, 2008, the Company repurchased 394,711 shares through the stock repurchase plan at an average share price of $42.22 per share for an aggregate cost of $16.7 million (excluding broker commissions).

Off-Balance Sheet Arrangements.    As of September 30, 2008,March 31, 2009, the Company has no material off-balance sheet arrangements.

        New2008 Credit Facility.    On April 30, 2008, the Company's credit agreement with Deutsche Bank AG dated January 5, 2004, as amended (the "Credit Agreement")Credit Agreement was terminated, and the Company entered into the New Credit Facility which providesa credit facility with Deutsche Bank AG and Citigroup Global Markets Inc. that provided for a $100.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans.loans (the "2008 Credit Facility"). Borrowings under the New2008 Credit Facility, will matureif any, matured on April 29, 2009. The New2008 Credit Facility iswas guaranteed by substantially all of the subsidiaries of the Company and iswas secured by substantially all of the assets of the Company and the subsidiary guarantors.


        Under the New2008 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to the sum of (i) a borrowing margin of 1.00 percent plus (ii) (A) in the case of U.S. dollar denominated loans, the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (B) in the case of Eurodollar denominated loans, an interest rate which is a function of the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 1.125 percent. The


Table of Contents


commitment commission on the New2008 Credit Facility was 0.375 percent of the unused Revolving Loan Commitment.

        On April 29, 2009, the Company entered into an amendment to the 2008 Credit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company with a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will be 0.375mature on April 28, 2010. The 2009 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the 2009 Credit Facility is 0.625 percent of the unused Revolving Loan Commitment.

        Restrictive Covenants in Debt Agreements.    The New2009 Credit Facility contains covenants that limit management's discretion in operating the Company's business by restricting or limiting the Company's ability, among other things, to:

        These restrictions could adversely affect the Company's ability to finance future operations or capital needs or engage in other business activities that may be in the Company's interest.

        The New2009 Credit Facility also requires the Company to comply with specified financial ratios and tests. Failure to do so, unless waived by the lenders under the New2009 Credit Facility pursuant to itstheir terms, would result in an event of default under the New Credit Facility.such credit facilities.

        Net Operating Loss Carryforwards.    The Company estimates that it had reportable federal NOLs as of December 31, 20072008 of approximately $238.9$124.5 million available to reduce future federal taxable income. These estimated NOLs expire in 2011 through 2020 and are subject to examination and adjustment by the IRS. In addition, the Company's utilization of such NOLs is subject to limitation under Internal Revenue Code Section 382, which affects the timing of the use of these NOLs. At this time, the Company does not believe these limitations will limit the Company's ability to use any federal NOLs before they expire. Although the Company has NOLs that may be available to offset future taxable income, the Company may be subject to Federal Alternative Minimum Tax.


Table of Contents

        As of December 31, 2007,2008, the Company's valuation allowances against deferred tax assets were $10.2$9.4 million, mostly forrelating to uncertainties regarding the eventual realization of certain state NOLs and other state deferred tax assets. TheDetermination of the amount of deferred tax assets considered realizable required significant judgment and estimation. Changes in these estimates in the future could materially affect the Company's financial condition and results of operations.

Recent Accounting Pronouncements

        In September 2006, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards ("SFAS") No. 157 "Fair Value Measurements" ("SFAS 157").



SFAS 157, which provides guidance for using fair value to measure assets and liabilities. It also responds to investors' requests for expanded information about the extent to which companies measure assets and liabilities at fair value, the information used to measure fair value and the effect of fair value measurements on earnings. SFAS 157 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value, and does not expand the use of fair value in any new circumstances. SFAS 157 is effective for fiscal years beginning after November 15, 2007. In February 2008, the FASB issued FASB Staff Position No. 157-2, Effective Date of FASB Statement No. 157 ("FSP 157-2"), which delays the effective date of SFAS 157 by one year for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). On January 1, 2008, the Company adopted SFAS 157 for financial assets and liabilities. The adoption did not have a material impact on the consolidated financial statements. TheOn January 1, 2009, the Company has not yet determined the impact on its consolidated financial statements, if any, from the adoption ofadopted SFAS 157 as it pertains tofor non-financial assets and non-financial liabilities.

        In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115" ("SFAS 159"). SFAS 159 permits entities to elect to measure financial instruments and certain other items at fair value. The objective is to improve financial reporting by allowing entities to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. SFAS 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. SFAS 159 was effective for the Company on January 1, 2008. The Companyadoption did not electhave a material impact on the fair value option for any of the Company's existingconsolidated financial instruments on January 1, 2008 and has not determined whether or not the Company will elect this option for any eligible financial instruments the Company acquires in the future.statements.

        In December 2007, the FASB issued SFAS No. 141(R) "Business Combinations" ("SFAS 141(R)") and SFAS No. 160, "Non-controlling Interests in Consolidated Financial Statements" ("SFAS 160"). SFAS 141(R) requires the acquiring entity in a business combination to record all assets acquired and liabilities assumed at their respective acquisition-date fair values and changes other practices under SFAS 141, some of which could have a material impact on how the Company accounts for future business combinations. SFAS 141(R) also requires additional disclosure of information surrounding a business combination, such that users of the entity's financial statements can fully understand the nature and financial impact of the business combination. SFAS 160 requires entities to report non-controlling (minority) interests in subsidiaries as equity in the consolidated financial statements. The Company is required to adoptadopted SFAS 141(R) and SFAS 160 simultaneously in the Company's year beginning January 1, 2009. The Company is currently evaluatingPrior to 2009 and in accordance with American Institute of Certified Public Accountants ("AICPA") Statement of Position ("SOP") 90-7, "Financial Reporting by Entities in Reorganization Under the effects, if any, thatBankruptcy Code" ("SOP 90-7"), reversals of both valuation allowances and unrecognized tax benefits with respect to years prior to the Company's reorganization were recorded to goodwill. All other reversals of these balances were recorded as reductions to income tax expense. As a result of the implementation of SFAS 141(R), beginning in 2009 all reversals of valuation allowances and unrecognized tax benefits are reflected as reductions to income tax expense, even if related to years prior to the Company's reorganization. The adoption of SFAS 160 maydid not have a material impact on the Company's consolidated financial position and results of operations.statements.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

        Changes in interest rates affect interest income earned on the Company's cash equivalents and restricted cash and investments, as well as interest expense on variable interest rate borrowings under the New2008 Credit Facility. Based on the Company's investment balances, and the borrowing levels under the New2008 Credit Facility as of September 30, 2008,March 31, 2009, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.


Table of Contents


Item 4.    Controls and Procedures.

        a)    The Company's management evaluated, with the participation of the Company's principal executive and principal financial officers, the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) under the Exchange Act), as of September 30, 2008.March 31, 2009. Based


on their evaluation, the Company's principal executive and principal financial officers concluded that the Company's disclosure controls and procedures were effective as of September 30, 2008.March 31, 2009.

        b)    Under the supervision and with the participation of management, including the Company's principal executive and principal financial officers, the Company has determined that there has been no change in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the Company's quarter ended September 30, 2008March 31, 2009 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.


Table of Contents


PART II—OTHER INFORMATION

Item 1.    Legal Proceedings.

        The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense. The Company is also subject to or party to certain class actions, litigation and claims relating to its operations andor business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

Item 1A.    Risk Factors.

The value of the Company's investments is influenced by varying economic and market conditions, and a decrease in value may result in a loss charged to income.

        The Company's available-for-sale investment securities were $542.7 million and represented 35.9 percent of the Company's total consolidated assets at September 30, 2008. These assets are carried at fair value, and the unrealized gains or losses are included in accumulated other comprehensive income as a separate component of shareholders' equity, unless the decline in value is deemed to be other-than-temporary. If a decline in value is deemed to be other-than-temporary, the cost basis of the impaired security is written down to fair value and a charge is taken through operations. The Company has concluded that the unrealized losses are temporary and the Company has the intent and ability to hold the securities until they recover or mature. Therefore, the Company has not recorded any other than temporary impairments.

        In accordance with applicable accounting standards, the Company reviews its investment securities to determine if declines in fair value below cost are other-than-temporary. This review is subjective and requires a high degree of judgment. The Company conducts this review on a quarterly basis, using both quantitative and qualitative factors, to determine whether a decline in value is other-than-temporary. Such factors considered include the length of time and the extent to which market value has been less than cost, financial condition and near term prospects of the issuer, trading activity and marketability of the security, recommendations of investment advisors and forecasts of economic, market or industry trends. This review process also entails an evaluation of the Company's ability and intent to hold individual securities until they mature or full cost can be recovered. The current economic environment and recent volatility of securities markets increase the difficulty of assessing investment impairment and the same influences tend to increase the risk of potential impairment of these assets. The Company believes it has adequately reviewed its investment securities for impairment and that its investment securities are carried at fair value. However, over time, the economic and market environment may provide additional insight regarding the fair value of certain securities, which could change the Company's judgment regarding impairment. This could result in realized losses relating to other-than-temporary declines being charged against future income. Given the current market conditions and the significant judgments involved, there is a risk that declines in fair value may occur



and material other-than-temporary impairments may be charged to income in future periods, resulting in realized losses.

General economic conditions

        The state of the national economy and adverse changes in economic conditions could adversely affect the Company's business and results of operations. The state of the economy has negatively affected state budgets and could adversely affect the Company's reimbursement from state Medicaid programs in its Public Sector segment. The state of the economy and adverse economic conditions could also adversely affect our customers in the Commercial, Radiology Benefits Management and Specialty Pharmaceutical Management segments and the membership in our customers' health plans could drop, potentially causing a drop in the membership served by the Company, and thereby adversely affecting the revenues to the Company from such customers.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

        On July 30, 2008 the Company's board of directors approved a stock repurchase plan which authorizes the Company to purchase up to $200 million of its outstanding common stock through January 31, 2010. Stock repurchases under the program may be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deems appropriate. The stock repurchase program may be limited or terminated at any time without prior notice. Pursuant to this program, the Company made open market purchases of 394,7111,799,933 shares of the Company's common stock at an average share price of $34.32 per share for an aggregate cost of $16.7$61.8 million (excluding broker commissions and transaction fees)commissions) during the three months ended September 30, 2008.March 31, 2009. As of March 31, 2009, the amount of stock repurchases that remained under the program was $2.2 million and such remaining repurchases were made during the period subsequent to March 31, 2009, completing the repurchase program as of April 7, 2009.

        Following is a summary of stock repurchases made duringfrom January 1, 2009 through the three month period ended September 30, 2008:completion of the repurchase program on April 7, 2009:

Period
 Total number
of Shares
Purchased
 Average
Price Paid
per Share(2)
 Total Number
of Shares
Purchased as
Part of Publicly
Announced Plans
or Programs
 Approximate Dollar
Value of Shares
that May Yet
Be Purchased
Under the Plan(1)(2)
 

July 1 - 31, 2008

       $200,000 

August 1 - 30, 2008

  49,026 $43.68  49,026  197,859 

September 1 - 30, 2008

  345,685 $42.01  345,685  183,336 
          

  394,711 $42.22  394,711  183,336 
          
Period
 Total number
of Shares
Purchased
 Average
Price Paid
per Share(2)
 Total Number of Shares
Purchased as Part of Publicly
Announced Plans or Programs
 Approximate Dollar Value
(in thousands) of Shares that
May Yet Be Purchased
Under the Plan(1)(2)
 

January 1-31, 2009

  117,200 $37.36  117,200 $59,585 

February 1-28, 2009

  422,000 $34.72  422,000  44,932 

March 1-31, 2009

  1,260,733 $33.91  1,260,733  2,185 

April 1-7, 2009

  60,026 $36.42  60,026   
           

  1,859,959     1,859,959   
           

(1)
Excludes amounts that could be used to repurchase shares acquired under the Company's equity incentive plans to satisfy withholding tax obligations of employees and non-employee directors upon the vesting of restricted stock units.

(2)
Excludes broker commissions and transaction fees.

Table of Contents

Item 3.    Defaults Upon Senior Securities.

        None.

Item 4.    Submission of Matters to a Vote of Security Holders.

        None.



Item 5.    Other Information.

        (i) 2009 Credit Facility:    On OctoberApril 29, 2009, the Company entered into an amendment to the 2008 Barry M. Smith, a directorCredit Facility with Deutsche Bank AG, Citibank, N.A., and Bank of America, N.A. that provides for an $80.0 million Revolving Loan Commitment for the issuance of letters of credit for the account of the Company since 2004, resigned his positionwith a sublimit of up to $30.0 million for revolving loans (the "2009 Credit Facility"). Borrowings under the 2009 Credit Facility will mature on April 28, 2010. The 2009 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors.

        Under the 2009 Credit Facility, the annual interest rate on Revolving Loan borrowings bear interest at a rate equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 2.25 percent plus the higher of the prime rate or one-half of one percent in excess of the overnight "federal funds" rate, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 3.25 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of Credit issued under the Revolving Loan Commitment bear interest at the rate of 3.375 percent. The commitment commission on the Board as a result of his acceptance of a non-paid position as an official2009 Credit Facility is 0.625 percent of the Churchunused Revolving Loan Commitment.

        (ii) Managed Behavioral Health Contract:    As previously reported, the Company has a managed behavioral healthcare contract with a customer that extends through June 30, 2009 and generated net revenues of Jesus Christ of Latter Day Saints in Dallas. Smith serves as a Mission President$90.8 million for the church in north Texasyear ended December 31, 2008. On April 30, 2009, the Company and due toits customer entered into a new contract with a term expiring June 30, 2014, terminable without cause upon 180 days' notice after the requirementsthird anniversary of the position, will no longer be ablecontract. The contract is expected to serve on public or private boardsgenerate revenues in excess of $90 million during his three-year term in that role. The Nominating and Corporate Governance Committee of the board has commenced a search for a new director to replace Mr. Smith.fiscal 2009.

Item 6.    Exhibits.Exhibits

 31.14.1 Second Amendment to Credit Agreement, dated as of April 29, 2009, among Magellan Health Services, Inc., various lenders and Deutsche Bank AG New York Branch, as administrative agent.


31.1


Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.

 

31.2

 

Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1

 

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2

 

Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents


SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: October 31, 2008April 30, 2009 MAGELLAN HEALTH SERVICES, INC.
(Registrant)

 

 

By:

 

/s/ JONATHAN N. RUBIN

Jonathan N. Rubin
Executive Vice President and Chief Financial
Officer
(Principal (Principal Financial Officer and Duly
Authorized Officer)



QuickLinks

INDEX
PART I—FINANCIAL INFORMATION
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts)
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts)
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, (Unaudited) (In thousands)
MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 2008 (Unaudited)
PART II—OTHER INFORMATION
SIGNATURES